WO2017047097A1 - 構造強化されたmiRNA阻害剤S-TuD - Google Patents
構造強化されたmiRNA阻害剤S-TuD Download PDFInfo
- Publication number
- WO2017047097A1 WO2017047097A1 PCT/JP2016/004252 JP2016004252W WO2017047097A1 WO 2017047097 A1 WO2017047097 A1 WO 2017047097A1 JP 2016004252 W JP2016004252 W JP 2016004252W WO 2017047097 A1 WO2017047097 A1 WO 2017047097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- bna
- double
- mirna
- stranded
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Definitions
- the present invention relates to a miRNA inhibitor with enhanced structure.
- the present invention provides the following. (1) a miRNA inhibition complex comprising RNA or an analog thereof, wherein the miRNA inhibition complex comprises at least one double-stranded structure and a miRNA binding sequence, wherein the two strands of the miRNA binding sequence are A miRNA-inhibiting complex, wherein the miRNA-inhibiting complex comprises at least one cross-linked nucleic acid (BNA), one bound to at least one strand of at least one end of a double-stranded structure. (2) The BNA contains at least one atom selected from the group consisting of oxygen and carbon on the 2 ′ position, and at least one atom selected from the group consisting of carbon, carbon and nitrogen on the 4 ′ position. 2. A complex according to item 1, comprising BNA cross-linked via. (3) The BNA is
- R 1 , R 1 ′, R 2 , R 2 ′, and R 3 each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, substituted or non-substituted, Substituted cycloalkyl group, substituted or unsubstituted aryl group, substituted or unsubstituted aralkyl group, substituted or unsubstituted acyl group, substituted or unsubstituted sulfonyl group, substituted or unsubstituted silyl group, and functional molecule
- Base is from an adenylyl group, a thyminyl group, a urasilyl group, an inosinyl group, a cytosynyl group, a guan
- R 3 is selected from the group consisting of a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, an aralkyl group, an acyl group, a sulfonyl group, a silyl group, and a functional molecular unit substituent.
- Base represents a group selected from the group consisting of an adenylyl group, a thyminyl group, a urasilyl group, an inosinyl group, a cytosynyl group, a guaninyl group, and a methylcytosynyl group, and a methylcytosynyl group, and m is an integer of 0 to 2, 4.
- the complex according to any one of items 1 to 3, comprising a 2 ′, 4′-substituted cross-linked nucleic acid represented by the following formula: n is an integer of 1 to 3. (5)
- the complex according to any one of items 1 to 4 comprising 2 ′, 4 ′ methano-bridged nucleic acid (LNA).
- LNA methano-bridged nucleic acid
- (6) The complex according to any one of items 1 to 5, wherein the BNA is BNA NC (NMe).
- NMe BNA NC
- (7) The complex according to any one of items 1 to 6, wherein the BNA is contained in at least one strand of the double-stranded structure moiety and at least one strand of a complementary strand of the miRNA binding sequence.
- (9) The complex according to any one of items 1 to 8, wherein the BNA is contained in both chains of the double-stranded structure moiety.
- (13) The complex includes two or more of the double-stranded structures, and each of the two strands at one end of the first double-stranded structure of the double-stranded structure includes one strand containing a miRNA binding sequence. Two strands of a second double-stranded structure of each of the two or more double-stranded structures so that each other end of the chain is bound and sandwiched between the two or more double-stranded structures 13.
- the complex according to any one of items 1 to 17, wherein the double-stranded structure has a length of at least 10 bases.
- a complex comprising the structure shown in 1. wherein I and II of the structure are double-stranded structures, each comprising a miRNA binding sequence in a and b of the structure.
- 24A The complex according to any one of Items 1 to 24, wherein the double-stranded structure is in the form of a single-stranded nucleic acid in which the ends of each strand are bonded to each other.
- 24B The complex according to any one of items 1 to 24 or 24A, which is composed of linear single-stranded RNA or an analog thereof.
- the two strands containing the miRNA binding sequence are bound to two strands at one end of the double-stranded structure one by one through a linker of 1 to 5 bases each.
- Two strands comprising the miRNA binding sequence comprising a second multiple strand structure selected from double strands or quadruplexes and sandwiched between the double strand structure and the second multiple strand structure Any one of 1 to 24, 24A, or 24B, wherein the other end of each is bonded to two strands at one end of the second multi-stranded structure via a linker of 1 to 5 bases, respectively.
- a miRNA-inhibiting complex wherein the two strands containing the miRNA binding sequence are each one containing a miRNA binding sequence and two strands containing a miRNA binding sequence (24D)
- the complex according to any one of items 1 to 24, 24A, 24B or 24C, wherein the two strands comprising each comprises a miRNA binding sequence and there are two strands comprising a miRNA binding sequence.
- RNA constituting the complex according to any one of items 1 to 24, 24A, 24B, 24C or 24D or an analog thereof.
- a method for producing the complex according to any one of items 1 to 24, 24A, 24B, 24C, or 24D, or the RNA according to item 25 or an analog thereof A) A step of synthesizing a single-stranded protector of a target RNA or its analog and a protector of its complement using ribonucleic acid and BNA by chemical synthesis; B) a step of deprotecting each of the produced single-stranded protector and its complement; and, if necessary, C) two of the deprotected single strands arranged in double-strand formation conditions.
- a method comprising the step of forming a chain.
- a medicament comprising the complex according to any one of items 1 to 24, 24A, 24B, 24C or 24D.
- (27A) The complex according to any one of items 1 to 24, 24A, 24B, 24C or 24D for use as a medicament.
- (27B) A method for the treatment or prevention of a disease or disorder, comprising the step of administering a complex according to any one of items 1 to 24, 24A, 24B, 24C or 24D to a subject in need thereof.
- the improved S-TuD of the present invention has been found to have a miRNA inhibitory activity that is more stable than the conventional S-TuD and is not unexpectedly purified and has reduced impurities in pharmaceutical grade. It was. By strengthening the double strands, the cost can be reduced as STEM region shortened S-TuD having the same activity.
- the improved S-TuD of the present invention also has a significantly improved biological activity compared to the conventional S-TuD.
- FIG. 1A shows a schematic diagram of a conventional S-TuD and a partially substituted S-TuD of the present invention.
- FIG. 1B shows a comparison of S, AS, and double strands analyzed by reverse phase HPLC (RP-HPLC) analysis of conventional S-TuD (C18 reverse phase ion pair HPLC, XBridge column).
- FIG. 2A shows the structure of the oligonucleotide used. The top row shows the original oligonucleotide, and the second and subsequent rows are modified oligonucleotides.
- FIG. 2B shows the structure of the oligonucleotide used.
- FIG. 3 shows the structure of psiCHECK2-UT (top) and psiCHECK2-miRT (bottom).
- FIG. 4-1 shows the structure of the oligo used.
- FIG. 4-2 shows the results of the miR-199a-3p reporter assay of the oligo of FIG. 4-1. Bars indicate the ratio of control reporter activity to miR-199a-3p reporter inhibitor activity. The higher the inhibitory effect of S-TuD, the higher the bar.
- FIG. 5 shows the concentration dependency of various modified S-TuD199a-3p. As the cell, HeLaS3-miR199a was used.
- FIG. 6 shows the structure of S-TuD (S-TuD199a-3p) used in the substitution experiment for the MBS region. The upper row shows the structure of the original S-TuD199a-3p-1_18-pf.
- the modified S-TuD of the present invention is (16) S-TuD-miR-199a-3p-1_18-pf-L18B6-2, (22) S-TuD-miR-199a-3p-1_18- pf-L18B6-2-MBSB1 (complement of the seed region into BNA NC (NMe)), (23) S-TuD-miR-199a-3p-1_18-pf-L18B6-2-MBSB2 (complement of the non-seed region) The sequence is BNA NC (NMe)), (24) S-TuD-miR-199a-3p-1_18-pf-L18B6-3-MBSB2 (the complementary sequence of the non-seed region is BNA NC (NMe)).
- FIG. 7 shows the structure of S-TuD used in the substitution experiment to the MBS region.
- S-TuD199a-3p-1_18-pf-S10-BT6-MBSB1 complementary sequence of the seed region is converted to BNA NC (NMe)
- S-TuD199a-3p-1_18-pf -S10-BT6-MBSB2 complementary sequence of non-seed region is converted to BNA NC (NMe)
- (23) - (2 ) S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS2 the complementary sequence of the non-seed region BNA NC (NMe)
- FIG. 8-1 and FIG. 8-2 show the results of replacement of part of the MBS region with BNA NC (NMe). As shown in FIGS. 8-1 and 8-2, a structure in which the inhibitory activity was improved 3 times or more compared to the original S-TuD could be obtained. It was important to insert a portion of BNA NC (NMe) into the non-seed region of the MBS region.
- FIG. 8-1 and FIG. 8-2 show the results of replacement of part of the MBS region with BNA NC (NMe). As shown in FIGS. 8-1 and 8-2, a structure in which the inhibitory activity was improved 3 times or more compared to the original S-TuD could be obtained.
- the result of having performed the concentration dependence test is shown.
- the diamond indicates S 2 -TuD NC2 (SEQ ID NOs: 57 and 58), the square indicates the original, and the triangle indicates (18).
- FIG. 10 shows the structure of S-TuD used in the experiment for confirming the effect of inserting the BNA NC (NMe) into the STEM region shortening + MBS region.
- the upper part shows the original structure of S-TuD199a-3p.
- FIG. 11-1 shows the results at 100 pM.
- the effect of BNA NC (NMe) modification on the short type was examined.
- the original and long type Stem-BNA NC (NMe) modifications (16) were added to the comparison.
- Short type-BNA NC (NMe) unmodified (1) ′ the effect of (6) ′ with BNA NC (NMe) modification in the stem portion was greatly enhanced.
- addition of BNA NC (NMe) modification to the Seed equivalent site (17) did not enhance the effect.
- FIG. 11-1 and FIG. 11-2 show the results (3 ⁇ T199a-3p / UT (%)) at individual S-TuD 100 pM and 300 pM.
- FIG. 11-2 shows the results at 300 pM.
- the effect of BNA NC (NMe) modification on the short type was examined. The original and long type Stem-BNA NC (NMe) modifications (16) were added to the comparison.
- FIG. 12 shows the structure of the modified S-TuD used in the stability experiment in serum. The top is the original structure.
- FIG. 13 shows the structure of modified S-TuD used in serum stability experiments. From above, (1) 'S-TuD199a-3p-1_18-pf-S10, (6)' S-TuD199a-3p-1_18-pf-S10-BT6, (17) S-TuD199a-3p-1_18-pf- S10-BT6-MBSB1 (complementary sequence of seed region is converted to BNA NC (NMe)) and (18) S-TuD199a-3p-1_18-pf-S10-BT6-MBSB2 (complementary sequence of non-seed region is converted to BNA NC (NMe) )).
- FIG. 14 shows an electropherogram after treatment with mouse serum.
- FIG. 15 shows an electropherogram. (1) 'S-TuD199a-3p-1_18-pf-S10, (6)' S-TuD199a-3p-1_18-pf-S10-BT6 from the upper left, (17) S-TuD199a-3p from the lower left -1_18-pf-S10-BT6-MBSB1 (complementary sequence of seed region converted to BNA NC (NMe)) and (18) S-TuD199a-3p-1_18-pf-S10-BT6-MBSB2 (complementary sequence of non-seed region) Is converted to BNA NC (NMe).
- FIG. 16 shows a schematic diagram of the luciferase reporter vector used in the examples.
- FIG. 16 shows a schematic diagram of the luciferase reporter vector used in the examples.
- FIG. 17 shows the psiCHECK2-T200c-3p-s, psiCHECK2-T200c-3p-a, psiCHECK2-T199a-3px3-s, psiCHECK2-T199a-3px3-a, psiCHECK2-T21-5p-s used in the luciferase reporter vector. , Shows the sequence information of psiCHECK2-T21-5p-a. These sequences (SEQ ID NOs: 75 to 80) are all unmodified DNA.
- FIG. 18 shows the arrangement of S-TuD-NC2 used in the examples.
- FIG. 19 shows the S-TuD structure of miR-200c used in the universality confirmation experiment.
- FIG. 20 shows an electropherogram after treatment with mouse serum. 0h, 24h, 48h and 72h indicate the time of treatment in mouse serum at 37 ° C. From left, (41) S-TuD-200c-1_22-pf, (42) S-TuD-200c-1_22-pf-L18B6, (44) S-TuD-200c-1_22-pf-L18B6-MBSB2, (45 ) S-TuD-200c-1_22-pf-S10-BT6-MBSB2, (46) S-TuD-200c-1_22-pf-S10-BT6, and the numbers indicate time.
- FIG. 21-1 shows the 3 pM results. Bars indicate the ratio of control reporter activity to miR-199a-3p reporter inhibitor activity. The higher the inhibitory effect of S-TuD, the higher the bar.
- FIG. 21-1 and FIG. 21-2 show the results of performing a reporter assay similar to miR199a-3p with miR-200c.
- FIG. 21-2 shows the result of 10 pM. Bars indicate the ratio of control reporter activity to miR-199a-3p reporter inhibitor activity. The higher the inhibitory effect of S-TuD, the higher the bar.
- FIG. 22 shows the results showing the concentration dependency of the same reporter assay with miR-200c.
- the diamond indicates S-TuD NC2, the square indicates the original, and the triangle indicates (45).
- Stem is BNA NC (NMe)
- the complementary sequence of the non-seed region of the MBS is further modified with BNA NC (NMe) (45) is modified with BNA NC (NMe)
- BNA NC NMe
- the effect was almost twice as high as that of original (41).
- S-TuD could be adsorbed non-specifically on the tube, and S-TuD NC2 was added as a carrier, and 30 pM was also analyzed, but the effect of addition was not observed.
- FIG. 23 shows the S-TuD structure of miR-21 used in the universality confirmation experiment.
- FIG. 24 shows an electropherogram after treatment with mouse serum. 0h, 24h, 48h and 72h indicate the time of treatment in mouse serum at 37 ° C.
- FIGS. 25-1 and 25-2 show the results of a similar reporter assay performed with miR-21.
- FIG. 25-1 shows the result of 100 pM. Bars indicate the ratio of control reporter activity to miR-199a-3p reporter inhibitor activity. The higher the inhibitory effect of S-TuD, the higher the bar.
- FIGS. 25-1 and 25-2 show the results of a similar reporter assay performed with miR-21.
- FIG. 25-1 shows the result of 100 pM. Bars indicate the ratio of control reporter activity to miR-199a-3p reporter inhibitor activity. The higher the inhibitory effect of S-TuD, the higher the bar.
- FIG. 25-1 and 25-2 show the results of a similar reporter assay performed with miR-21.
- FIG. 25-2 shows the results at 300 pM. Bars indicate the ratio of control reporter activity to miR-199a-3p reporter inhibitor activity. The higher the inhibitory effect of S-TuD, the higher the bar.
- FIG. 26 shows the results showing the concentration dependency of the same reporter assay with miR-21. Compared with Original No. 51 (square), No. 53 (triangle) in which the stem portion and MBS portion were modified with BNA NC (NMe) had an effect increased nearly 10 times. Even in the short type, the 55 (x) modified MBS part was more than 3 times more effective than the original 51, but about 2/3 times the long type 53. Diamonds indicate controls.
- FIG. 51 square
- No. 53 triangle
- the stem portion and MBS portion were modified with BNA NC (NMe) had an effect increased nearly 10 times. Even in the short type, the 55 (x) modified MBS part was more than 3 times more effective than the original 51, but
- FIG. 27 shows the structure of S-TuD used in in vivo experiments. From above, (51) S-TuD-21-1_17-10mut, (53) S-TuD-21-1_17-10mut-L18B6-MBSB1 and (55) S-TuD-21-1_17-10mut-S10-BT6- Indicates MBSB1.
- FIG. 29 shows the mean value of miR-21 in the kidneys of three mice. The least amount of miR-21 is 53, followed by 55. The original S-TuD shows almost no reduction in miR-21, but a decrease is detected even at 53 and 55, although the degree is slightly reduced.
- FIG. 30 shows a typical structure of the miRNA-inhibiting complex of the present invention, where two RNA strands containing MBS are sandwiched between two double stranded structures. The form in which each chain is bound is shown.
- FIG. 31 also shows a typical structure of the miRNA inhibition complex of the present invention, where # 12 to # 16 are shown as typical examples.
- FIG. 32 shows an exemplary arrangement used in Example 7.
- the sequence used was the original, (5) S-Tud199a-3p-1_18-pf-U4BNA_SI-8; (1) 'S-TuD199a-3p-1_18-pf-S10; (2)' S-TuD199a -3p-1_18-pf-S10-BT8; (6) 'S-TuD199a-3p-1_18-pf-S10-BT6; (7)' S-TuD199a-3p-1_18-pf-S10-LT6; (8) 'Shows S-TuD199a-3p-1_18-pf-S10-BT12.
- FIGS. 33-1 and 33-2 show the assay results of Example 7.
- FIG. The 8 samples in FIG. 33-1 show the results at 100 pM. The left end of each is a control, and the 2nd to 8th from the left show the results of each sample.
- FIGS. 33-1 and 33-2 show the assay results of Example 7.
- FIG. The 8 samples in FIG. 33-2 show the results at 300 pM. The left end of each is a control, and the 2nd to 8th from the left show the results of each sample.
- FIG. 34 shows an example of arrangement used in Example 8.
- FIG. 35-1 and 35-2 show the assay results of Example 8.
- FIG. The 8 samples in FIG. 35-2 show the results at 3 nM.
- the left end of each is a control, and the 2nd to 8th from the left show the results of each sample.
- FIG. 36 shows an example of arrangement used in Example 9.
- FIGS. 37-1 and 37-2 show the assay results of Example 9.
- FIG. The 8 samples in FIG. 37-1 show the results at 100 pM. The left end of each is a control, and the 2nd to 8th from the left show the results of each sample.
- FIGS. 37-1 and 37-2 show the assay results of Example 9.
- FIG. The 8 samples in Fig. 37-2 show the results at 300 pM. The left end of each is a control, and the 2nd to 8th from the left show the results of each sample.
- FIG. 38 shows the results (HPLC purity analysis) of changing the partial base of the STEM region to a nucleotide species (BNA NC (NMe)) of a type that increases the ability to form double strands and performing physical property evaluation.
- the upper row is the original one, and the lower row shows the result obtained in (1) ′ of the present invention.
- FIG. 39-1 and 39-2 show the ability to form double strands when only the 2′-O-methyl body is the same as the original S-TuD when the STEM I region is cut to 10 bp.
- FIG. 39-1 shows the results of (1) and (2) ′′ from above.
- FIGS. 39-1 and 39-2 show the ability to form double strands when only the 2′-O-methyl body is the same as the original S-TuD when the STEM I region is cut to 10 bp.
- FIG. 39-2 shows the results of (1) ′′ and (3) ′′ from above.
- FIG. 40 is a continuation of FIG. 39-1 and FIG. 39-2, and shows the results of (4) ′′ and (5) ′′ from above.
- the present invention relates to an improved form of a miRNA inhibition complex capable of efficiently and specifically inhibiting miRNA.
- the miRNA-inhibiting complex of the present invention comprises at least one double-stranded structure and an miRNA binding sequence (MBS), and the two strands of the miRNA binding sequence are at least two strands of the double-stranded structure (usually , One each), in addition, the miRNA-inhibiting complex is characterized in that it comprises at least one cross-linked nucleic acid (BNA).
- BNA cross-linked nucleic acid
- the inhibitory complex of the present invention may be referred to as “S-TuD”.
- this double-stranded structure may be referred to as a “first” double-stranded structure so that it can be distinguished from a further double-stranded structure that can be included in the complex of the present invention.
- the complex of the present invention may or may not be single-stranded (ie, a single molecule linked by a covalent bond). Good.
- a complex composed of double-stranded RNA in which RNA strands containing MBS are bound to two strands at one end of a double-stranded structure, respectively, contains at least one cross-linked nucleic acid (BNA, for example, , BNA NC (NMe)) are included in the present invention.
- one RNA strand containing at least one MBS may be bound to two strands at one end of a double-stranded structure.
- the two strands at one end of the double-stranded structure are connected by the RNA strand containing MBS.
- the RNA connecting two strands of a double-stranded structure contains at least one MBS, but may contain, for example, two, three, or more.
- Double-stranded structures include stem loops or hairpins. That is, the double-stranded structure may be a double-stranded structure contained in a stem loop or hairpin.
- the “seed region” refers to a region of about 2-8 bases from the 5 ′ end necessary for miRNA activity in the miRNA sequence, and the “stem region” refers to a double-stranded region.
- Point to. “Original” refers to the conventional “All 2′-OMe RNA type”, that is, a type composed entirely of 2′-OMe RNA, and is exemplified in Patent Document 1 and the like .
- the miRNA-inhibiting complex may be a structure having at least one RNA or an analog thereof having a double-stranded structure.
- the complex preferably comprises one or two molecules comprising RNA or an analog thereof.
- MBS miRNA binding sequence
- MBS refers to a sequence that binds to miRNA.
- the MBS contains at least a portion complementary to the miRNA so that it can bind to the miRNA.
- MBS may or may not be a completely complementary sequence to miRNA.
- MBS may be a sequence of natural RNA targeted by miRNA.
- MBS is, for example, at least 10 bases for miRNA, such as 11 bases or more, 12 bases or more, 13 bases or more, 14 bases or more, 15 bases or more, 16 bases or more, 17 bases or more, 18 bases or more, 19 bases or more, Complementary bases of 20 bases or more, 21 bases or more, 22 bases or more, 23 bases or more, or 24 bases or more are included consecutively or discontinuously.
- the complementary bases are continuous or have a gap of 3 or less, 2 or less, preferably 1 site.
- the gap may be MBS-side and / or miRNA-side unpairing (bulge), or one gap may have bulge bases on only one strand, and both strands are unpaired. It may have a paired base.
- the number of bulge and mismatch bases is, for example, 6 bases or less, preferably 5 bases or less, 4 bases or less, 3 bases or less, 2 bases or less, or 1 base per strand, per bulge or mismatch, respectively.
- MBS capable of forming a bulge showed a higher miRNA inhibitory effect than MBS consisting of a completely complementary sequence (Patent Document 1). Therefore, in order to obtain a higher miRNA inhibitory effect, it is preferable to design MBS so as to form a bulge.
- the 10th and / or 11th base from the 3 'end of MBS is not complementary to miRNA, or contains an extra base between 10th and 11th (or in miRNA
- the 10th and / or 11th base from the 5 'end of the target sequence is not a complementary base to MBS, or is unpaired between the 10th and 11th nucleotides MBS containing a combined base is less susceptible to degradation and can be expected to have high activity.
- the MBS may be designed so that bases including the 10th and 11th positions from the 5 ′ end of miRNA are unpaired, for example, 9th to 11th, 10th to 12th, or 9th to 12th
- the MBS may be designed so that is unpaired. There is no unpaired base on the miRNA side, but on the MBS side, between the 10th and 11th positions from the 3 ′ end (or 5 ′ of the target sequence in miRNA (sequence that hybridizes with MBS)). An unpaired base may be present between the 10th and 11th sites from the end).
- the unpaired base may be present on the miRNA side and / or MBS side, but is preferably present at least on the MBS side.
- the number of unpaired nucleotides in each strand can be adjusted as appropriate, and is, for example, 1 to 6 nucleotides, preferably 1 to 5 nucleotides, more preferably 3 to 5, for example 3, 4 or 5 It is a nucleotide.
- the miRNA-inhibiting RNA of the present invention has been shown to be able to effectively inhibit miRNA even if it has MBS that only matches the seed region and has only a low complementarity to other regions.
- Patent Document 1 those in which the seed region of miRNA (bases 2 to 7 and / or 3 to 8 from the 5 ′ end of miRNA) are completely complementary are preferable.
- G: U pairs (U: G pairs) may also be considered complementary, but preferably only G: C (C: G) and A: U (U: A) are considered complementary.
- the MBS includes a miRNA seed region (2-7th and / or 3-8th base from the 5 ′ end of the miRNA) that is completely complementary and at least 8 bases relative to the miRNA. More preferably, those containing 9 bases, more preferably 10 bases of complementary bases in succession are preferred. Furthermore, the MBS in the present invention preferably contains a total of 11 bases or more, more preferably 12 bases or more, and more preferably 13 bases or more complementary bases for miRNA.
- MBS is preferably a sequence that hybridizes with a miRNA sequence under physiological conditions.
- Physiological conditions are, for example, 150 mM NaCl, 15 mM sodium citrate, pH 7.0, 37 ° C. More preferably, the MBS is a sequence that hybridizes with the miRNA sequence under stringent conditions.
- the stringent conditions are, for example, 1 ⁇ SSC (1 ⁇ SSC is 150 mM NaCl, 15 mM sodium citrate, pH 7.0) or 0.5 ⁇ SSC, 42 ° C., more preferably 1 ⁇ SSC or 0.5 ⁇ .
- the conditions are SSC and 45 ° C., more preferably 1 ⁇ SSC or 0.5 ⁇ SSC and 50 ° C.
- Hybridization for example, either RNA containing miRNA sequence or RNA containing MBS is labeled, the other is immobilized on a membrane, and both are hybridized.
- Hybridization conditions include, for example, 5 ⁇ SSC, 7% (W / V) SDS, 100 ⁇ g / ml denatured salmon sperm DNA, 5 ⁇ Denhardt's solution (1 ⁇ Denhardt solution is 0.2% polyvinylpyrrolidone, 0.2% bovine serum albumin, and 0.2% Ficoll) For example, at 37 ° C., 45 ° C., or 50 ° C.
- the nucleic acid After incubating for a sufficient period of time (eg, 3, 4, 5 or 6 hours or more), washing is performed under the above conditions, and by detecting whether the labeled nucleic acid is hybridized, the nucleic acid is hybridized under the condition. Or not.
- a sufficient period of time eg, 3, 4, 5 or 6 hours or more
- MBS preferably exhibits high homology with the complementary sequence of the miRNA sequence.
- High homology means, for example, 70% or more, 75% or more, 76% or more, 77% or more, 78% or more, 79% or more, 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or higher, 86% or higher, 87% or higher, 88% or higher, 89% or higher, 90% or higher, 93% or higher, 95% or higher, 96% or higher, 97% or higher, 98% or higher, or 99% or higher It is a base sequence having sex. The identity of the base sequence can be determined using, for example, the BLAST program (Altschul, S.F. et al., J.
- MBS preferably consists of a sequence in which one or several bases are inserted, substituted, and / or deleted from the complementary sequence of the miRNA sequence.
- MBS is within 8 bases, within 7 bases, within 6 bases, within 5 bases, within 4 bases, within 3 bases, within 2 bases, or insertion, substitution of 1 base with respect to the complementary sequence of miRNA sequence, And / or consisting of sequences with deletions.
- the MBS has an insertion of within 8 bases, within 7 bases, within 6 bases, within 5 bases, within 4 bases, within 3 bases, within 2 bases, or 1 base relative to the complementary sequence of the miRNA sequence. Consists of an array.
- MBS has a higher miRNA inhibitory activity in a sequence having a mismatch than in a sequence completely complementary to the miRNA sequence. This is considered to be due to the fact that MBS is completely complementary and is cleaved by RISC containing miRNA, thereby reducing the expression level of miRNA-inhibiting RNA.
- MBS hybridizes with miRNA
- the 10th and / or 11th bases from the 3 ′ end of MBS are unpaired (or the 5 ′ end of the target sequence on the miRNA side that hybridizes with MBS)
- Such unpairing may be, for example, the bulge on the MBS side, and the base that forms the bulge is 1 to 6 bases, preferably 1 to 5 bases, more preferably 3 to 5 bases (eg 3, 4 or 5).
- Base may consist of RNA, or may contain or consist of nucleic acid salts.
- an increase in miRNA inhibitory effect can be expected by forming a nucleic acid salt at a site where MBS is cleaved (such as the 10th and / or 11th base from the 3 'end of MBS) so that cleavage does not occur.
- a nucleic acid having a backbone or sugar such as phosphothioate or 2 "-O-methyl (Krutzfeldt, J. et al., Nucleic Acids Res. 35: 2885-2892; Davis, S. et al. ., 2006, Nucleic Acids Res. 34: 2294-2304).
- the miRNA targeted by the miRNA inhibition complex of the present invention is not particularly limited. As long as it has an miRNA structure, it can be applied to any species such as plants, nematodes, vertebrates and the like.
- the number of miRNA sequences is very well known in many organisms, including humans, mice, chickens, zebrafish, and Arabidopsis (see the miRBase :: Sequences web page: microrna.sanger.ac.uk / sequences /).
- mammals such as mice, rats, goats, primates including monkeys, and human miRNAs can be targeted.
- miR21 (Lagos-Quintana M et al., Science.
- miR16 (Lagos-Quintana M et al., Science. 294: 853-858, 2001; Mourelatos Z et al., Genes Dev. 16: 720-728, 2002; Lim LP et al., Science. 299 : 1540, 2003; Calin GA et al., Proc Natl Acad Sci US A. 99: 15524-15529, 2002; Michael MZ et al., Mol Cancer Res. 1: 882-891, 2003), miR497 (Bentwich I et al., Nat Genet. 37: 766-770 , 2005; Landgraf P et al., Cell. 129: 1401-1414, 2007), etc., but is not limited thereto.
- the miRNA-inhibiting complex of the present invention further comprises a second double-stranded structure in addition to the first double-stranded structure, and the two strands at one end of the first double-stranded structure ,
- Each of the RNA strands containing MBS is bonded to each other, and the other end of each RNA strand is sandwiched between the first double-stranded structure and the second double-stranded structure.
- the double stranded structure may be double stranded, or may be four stranded like G-quadruplex.
- the present invention further includes a second double-stranded structure in addition to the first double-stranded structure, and the two strands at the ends to which MBS is bound in the first double-stranded structure have MBS.
- Each of the contained RNA strands is bonded to each other, and the other end of each RNA strand is inserted between the first double-stranded structure and the second double-stranded structure,
- the present invention relates to a miRNA-inhibiting complex that binds to each of the two strands of the second double-stranded structure.
- the RNA complex has, for example, at least two double-stranded structures, and each of the four RNA strands constituting the two double-stranded structures contains MBS without interposing any remaining three strands. It has a structure that binds to RNA.
- the miRNA-inhibiting complex can be explained more simply by binding to each strand of the two double-stranded structures so that the two RNA strands containing MBS are sandwiched between the two double-stranded structures.
- MiRNA inhibition complex (FIG. 30). That is, in the RNA complex having the structure of FIG.
- RNA strands a and b are sandwiched between double-stranded structures I and II, and RNA containing one or more MBS in each of a and b Included in the invention. Since the two RNA strands containing MBS are bound to the respective strands of the double-stranded structure, the directions of the RNA strands are opposite to each other (Fig. 31, # 12 to # 16). . Thus, by adding MBS to each double-stranded chain, it is possible to exhibit higher miRNA inhibitory activity.
- Two RNA strands including MBS present so as to be sandwiched between two double-stranded structures each contain one or more MBS. These MBSs may be the same sequence or different. Moreover, the same miRNA may be targeted and the sequence couple
- the miRNA-inhibiting complex of the present invention may contain a total of two MBS, and the two MBS may be the same sequence or a sequence that binds to the same miRNA.
- Each pair of duplexes included in the miRNA-inhibiting complex of the present invention is usually a separate RNA molecule as described above, but one or both ends of the duplex are connected to each other. It may be a chain or a ring.
- the term “linear” is a term for a ring and only means that it has a terminal, and naturally does not mean that a secondary structure is not formed.
- the miRNA inhibition complex composed of linear single-stranded RNA can be prepared, for example, by a single RNA synthesis. For example, when two double-stranded structures are included, two chains at one end of the second double-stranded structure (the side to which MBS is not bonded) can be connected by a loop to form a single strand as a whole. .
- One or more MBS may be included in the sequence connecting the double strands (for example, FIG. 31, # 13, # 14, # 16).
- the duplexes can be joined by short loops.
- the double strand can be combined with a sequence of 1 to 10 bases, preferably 1 to 8 bases, 2 to 6 bases, 3 to 5 bases, for example 4 bases.
- the arrangement is not particularly limited.
- the present invention relates to RNA having the structure of FIG. 31 # 13, in which RNA strands a and b are sandwiched between double-stranded structures I and II, and double-stranded structure II is a hairpin (or stem loop). And a and b each contain an RNA containing one or more MBS.
- the double-stranded structure contained in the miRNA-inhibiting complex of the present invention is not particularly limited in sequence, and may have an arbitrary base length.
- the preferred embodiment will be described separately in detail below.
- the sequence of base pairs forming a double-stranded structure can be appropriately designed so that a duplex can be specifically and stably formed in the miRNA-inhibiting complex.
- sequences in which several base sequences are repeated in tandem such as double base repeat sequences and 3-4 base repeat sequences.
- the GC content of the double-stranded portion may be adjusted as appropriate, for example, 12% to 85%, preferably 15% to 80%, 20% to 75%, 25% to 73%, 32% to 72%, 35% ⁇ 70%, 37% -68%, or 40% -65%.
- the sequences of stem I and stem II shown in Patent Document 1 can be exemplified, but are not limited thereto.
- the four strands include G-quadruplex, and specifically, a sequence of GGG-loop-GGG-loop-GGG-loop-GGG can be used.
- the sequence of the loop can be appropriately selected.
- all three loops can be 1 base (for example, M (A or C)), or both can be 3 bases.
- the MBS and the double-stranded structure may be linked directly or via other sequences.
- MBS can be attached to the end of a double stranded structure via a suitable linker or spacer sequence. Even if MBS is directly linked to the double-stranded portion, significant inhibitory activity can be obtained, but the inhibitory effect on miRNA is further increased by adding a linker (also referred to as a spacer) (see Patent Document 1).
- a linker or spacer sequence between the MBS sequence and the double-stranded structure may increase accessibility to miRNAs where MBS is present in RISC. The length of the linker or spacer may be appropriately adjusted.
- 1 to 10 bases preferably 1 to 9 bases, 1 to 8 bases, 1 to 7 bases, 1 to 6 bases, 1 to 5 bases, 1 to 4 Base, or 1-3 bases.
- the sequence of the linker or spacer is not particularly limited, and can be, for example, a sequence consisting of A and / or C, or a sequence containing A and / or C more than other bases.
- it is preferable to consider that the linker or spacer sequence does not form a stable base pair with the opposing linker or spacer sequence or MBS.
- AAC, CAA, ACC, CCA, or a sequence including any of them can be exemplified.
- a pair of linker or spacer sequences added to both sides of MBS may be an inverted sequence (mirror image sequence).
- AAC can be added to the 5 'side of the MBS and CAA can be added to the 3' side.
- the nucleic acid constituting the miRNA-inhibiting complex of the present invention is characterized by being modified with the specific modified nucleic acid of the present invention, but may contain modified nucleic acids other than the specific modified nucleic acid.
- the nucleotide constituting the nucleic acid may contain a natural nucleotide, a modified nucleotide, an artificial nucleotide, or a combination thereof, in addition to the specific modified nucleic acid of the present invention.
- the nucleic acid contained in the miRNA-inhibiting complex of the present invention may be composed of RNA or may be an RNA / DNA chimera other than the specific modified nucleic acid as long as it contains the specific modified nucleic acid of the present invention.
- nucleic acid includes not only those bound by a phosphodiester bond but also those having an amide bond or other backbone (such as peptide nucleic acid (PNA)).
- Nucleic acid analogs include, for example, natural and artificial nucleic acids, and may be nucleic acid derivatives, nucleic acid analogs, nucleic acid derivatives, and the like.
- Such nucleic acid analogs are well known in the art and include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral methylphosphonates, 2 "-O-methylribonucleotides, peptide nucleic acids (PNA), and the like.
- the PNA skeleton may include a skeleton composed of aminoethylglycine, polyamide, polyethyl, polythioamide, polysulfinamide, polysulfonamide, or a combination thereof (Krutzfeldt, J. et al., Nucleic Acids Res. 35: 2885-2892; Davis, S. et al., 2006, Nucleic Acids Res.
- BNA Bandd nucleic acid used in the present invention
- a specific type of modified nucleic acid includes a stabilized nucleic acid, that is, a modified nucleic acid that promotes double strand formation, including, for example, a broadly defined crosslinked nucleic acid (BNA).
- BNA crosslinked nucleic acid
- bridged nucleic acid (BNA) means both Bicyclic Nucleic Acid and Bridged Mucleic Acid. Also called “bridged nucleic acid”, “bicyclic nucleic acid” or “bridged / bicyclic nucleic acid”. .)) refers to any modified nucleic acid in which the 2′-position and 4′-position of the nucleic acid are linked (bridged) to form two (bicyclic) ring structures.
- a crosslinked nucleic acid can be used as the stabilized nucleic acid (that is, a modified nucleic acid that promotes double-stranded formation) used in the present invention.
- LNA locked nucleic acids
- ethylene nucleic acids such as 2 "-O, 4" -C-ethylene bridged nucleic acid (2 "-O, 4" -C-ethylene bridged nucleic acid (ENA)
- ENA locked nucleic acid
- BNA nucleic acid
- HNA hexitol nucleic acid
- tcDNA tricyclo-DNA
- tcDNA polyether nucleic acid
- CeNA cyclohexene nucleic acid
- substitution refers to replacement of a specific hydrogen atom in an organic compound such as a crosslinked nucleic acid (BNA) with another atom or atomic group.
- BNA crosslinked nucleic acid
- substituted refers to an atom or a functional group substituted with another in a chemical structure such as a crosslinked nucleic acid (BNA).
- BNA crosslinked nucleic acid
- substitution is the substitution of one or more hydrogen atoms in a certain organic compound or substituent with another atom or atomic group, or a double bond or triple bond. That means. It is possible to remove one hydrogen atom and replace it with a monovalent substituent, or combine with a single bond to form a double bond, and remove two hydrogen atoms to form a divalent substituent. It can be substituted or combined with a single bond to form a triple bond.
- alkyl refers to a monovalent group formed by loss of one hydrogen atom from an aliphatic hydrocarbon (alkane) such as methane, ethane, or propane, and is generally represented by C n H 2n + 1 —. Where n is a positive integer.
- Alkyl can be linear or branched. Specific examples thereof include C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C1-C6 alkyl, C1-C7 alkyl, C1-C8 alkyl, C1-C9 alkyl, C1-C10 alkyl.
- C1-C11 alkyl or C1-C20 alkyl C1-C2 substituted alkyl, C1-C3 substituted alkyl, C1-C4 substituted alkyl, C1-C5 substituted alkyl, C1-C6 substituted alkyl C1-C7 substituted alkyl, C1-C8 substituted alkyl, C1-C9 substituted alkyl, C1-C10 substituted alkyl, C1-C11 substituted alkyl or C1-C20 substituted alkyl obtain.
- C1-C10 alkyl means linear or branched alkyl having 1 to 10 carbon atoms.
- substituted alkyl refers to an alkyl in which H of alkyl is substituted by a substituent as defined herein. Specifically, but not limited to these, CH 3 OCH 2 —, CH 3 OCH 2 CH 2 —, CH 3 OCH 2 CH 2 CH 2 —, HOCH 2 —, HOCH 2 CH 2 —, HOCH 2 CH 2 CH 2 —, NCCH 2 —, NCCH 2 CH 2 —, NCCH 2 CH 2 CH 2 —, FCH 2 —, FCH 2 CH 2 —, FCH 2 CH 2 CH 2 —, H 2 NCH 2 —, H 2 NCH 2 CH 2 —, H 2 NCH 2 CH 2 CH 2 —, HOOCCH 2 —, HOOCCH 2 CH 2 —, HOOCCH 2 CH 2 CH 2 —.
- alkylene refers to a divalent group formed by losing two hydrogen atoms from an aliphatic hydrocarbon (alkane) such as methane, ethane, or propane, and is generally represented by —C n H 2n —. Where n is a positive integer.
- alkane aliphatic hydrocarbon
- the alkylene can be straight or branched.
- substituted alkylene refers to alkylene in which H of alkylene is substituted with the above-described substituent.
- C1-C10 alkylene means linear or branched alkylene having 1 to 10 carbon atoms.
- C1-C10 substituted alkylene refers to C1-C10 alkylene in which one or more hydrogen atoms are substituted with a substituent.
- alkylene may contain one or more atoms selected from an oxygen atom and a sulfur atom.
- cycloalkyl refers to alkyl having a cyclic structure.
- substituted cycloalkyl refers to a cycloalkyl in which H of the cycloalkyl is substituted by the above-described substituent. Specific examples include C3-C4 cycloalkyl, C3-C5 cycloalkyl, C3-C6 cycloalkyl, C3-C7 cycloalkyl, C3-C8 cycloalkyl, C3-C9 cycloalkyl, C3-C10 cycloalkyl, C3-C11.
- alkenyl refers to a monovalent group formed by losing one hydrogen atom from an aliphatic hydrocarbon having one double bond in the molecule, and is generally represented by C n H 2n-1 —. (Where n is a positive integer greater than or equal to 2). “Substituted alkenyl” refers to alkenyl in which H of alkenyl is substituted by the above-described substituent.
- C2-C10 alkyl means a straight-chain or branched alkenyl containing 2 to 10 carbon atoms.
- C2-C10 substituted alkenyl refers to C2-C10 alkenyl, in which one or more hydrogen atoms are substituted with substituents.
- aryl refers to a group formed by leaving one hydrogen atom bonded to an aromatic hydrocarbon ring, and is included in the present specification as a carbocyclic group. Phenyl group (C 6 H 5 —) from benzene, tolyl group (CH 3 C 6 H 4 —) from toluene, xylyl group ((CH 3 ) 2 C 6 H 3 —) from xylene, naphthyl from naphthalene The group (C 10 H 8 —) is derived.
- aralkyl means an alkyl group in which one of the hydrogen atoms of the alkyl group is substituted with an aryl group.
- Specific examples of the aralkyl group may be benzyl group, phenethyl group (phenylethyl group), 1-naphthylethyl and the like.
- acyl refers to a monovalent group formed by removing OH from a carboxylic acid.
- Representative examples of the acyl group include acetyl (CH 3 CO—), benzoyl (C 6 H 5 CO—), and the like.
- “Substituted acyl” refers to acyl hydrogen substituted with the above-described substituents.
- sulfonyl is a generic term for a substance including —SO 2 — which is a characteristic group. “Substituted sulfonyl” means sulfonyl substituted with the above-described substituents.
- sil is a group generally represented by SiR 1 R 2 R 3 — (wherein R 1 , R 2 and R 3 are each independently hydrogen, alkyl, cycloalkyl, Selected from the group consisting of alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkoxy, carbocyclic, heterocyclic. Specific examples thereof may be a trimethylsilyl group, a triethylsilyl group, a tri-n-propylsilyl group, a tert-butyldimethylsilyl group, a triisopropylsilyl group, or a tert-butyldiphenylsilyl group.
- “functional molecular unit substituent” means a labeled molecule (for example, a fluorescent molecule, a chemiluminescent molecule, a molecular species containing a radioisotope, etc.), a DNA or RNA cleaving active molecule, intracellular or nuclear translocation. A group containing a signal peptide or the like.
- the BNA is at least 1 selected from the group consisting of carbon, carbon and nitrogen on the 4 ′ position through at least one atom selected from the group consisting of oxygen and carbon on the 2 ′ position. It can be BNA bridged through one atom.
- the BNA used in the present invention is
- R 1 , R 1 ′, R 2 , R 2 ′, and R 3 each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, substituted or non-substituted, Substituted cycloalkyl group, substituted or unsubstituted aryl group, substituted or unsubstituted aralkyl group, substituted or unsubstituted acyl group, substituted or unsubstituted sulfonyl group, substituted or unsubstituted silyl group, and functional molecule
- a group selected from the group consisting of unit substituents such as, but not limited to, a substituted or unsubstituted phenoxyacetyl group, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 1 to 5 carbon atoms, carbon A lower aliphatic or aromatic group such as a
- Examples thereof include an aliphatic acyl group having 1 to 5 carbon atoms such as a phonyl group or an acetyl group, and an aromatic acyl group such as a benzoyl group, n is an integer of 1 to 3, and q is an integer of 0 or 1. 2), 4′-substituted cross-linked nucleic acid.
- Base is a purin-9-yl group, a 2-oxo-pyrimidin-1-yl group, or a derivative thereof, for example, but is not limited thereto, and is exemplified in Japanese Patent No. 4731324.
- 6-aminopurin-9-yl ie, adeninyl
- 2-amino-6-chloropurin-9-yl 2-amino-6-fluoropurin-9-yl
- 2-amino-6-bromopurine- 9-yl 2-amino-6-hydroxypurin-9-yl (ie, guaninyl)
- adeninyl thyminyl, guaninyl, uracilyl, Inoshiniru, a cytosinyl and 5 Mechirushitoshiniru and derivatives.
- the BNA used in the present invention is
- R 3 is a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl A group selected from the group consisting of a group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, a substituted or unsubstituted silyl group, and a functional molecular unit substituent, for example, but not limited thereto Is a phenoxyacetyl group, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 1 to 5 carbon atoms, an aryl group having 6 to 14 carbon atoms, a methyl group substituted with 1 to 3 aryl groups, a methane
- Base is similar to that described for BNA-1, and may preferably be adenylyl, guaninyl, thyminyl, uracinyl, inosinyl, cytosynyl and 5-methylcytosynyl, and derivatives thereof.
- the BNA used in the present invention is
- R 2 and R 2 ′ are each independently a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkyl group, A group selected from the group consisting of aryl groups, substituted or unsubstituted aralkyl groups, substituted or unsubstituted acyl groups, substituted or unsubstituted sulfonyl groups, substituted or unsubstituted silyl groups, and functional molecular unit substituents Examples include, but are not limited to, a methyl group and an O-methoxyethyl group, and Base is the same as described for BNA-1, preferably adenyl, guanylyl, thyminyl, uracinyl, inosinyl.
- BNA having a branch in the cross-linked chain is not limited to this.
- BNA (CEt: 2 ', 4'-constrained ethyl).
- BNA (cEt) has the same thermal stability and mismatch discrimination as conventional LNA, it is known to have improved stability against nucleases.
- the BNA used in the present invention is
- BNA NC (NMe) is displayed unless otherwise specified in the present specification, but “2 ′, 4′-BNANC” may also be displayed). Same definition as above, preferably selected from the group consisting of adenylyl, thyminyl, guaninyl, urasilyl, inosinyl, cytosynyl and 5-methylcytosinyl.
- protecting group refers to a group used to protect a functional group from a specific chemical reaction.
- the protecting group may be represented as “PG”.
- BNA NC NMe
- LNA LNA
- BNA NC NMe
- n is 1.
- the oligonucleotide may be a DNA oligonucleotide or RNA oligonucleotide containing one or more species, or a pharmacologically acceptable salt thereof.
- the bonding form between each nucleoside in the oligonucleotide is phosphorothioate bond [—OP (O) () in addition to the same phosphodiester bond [—OP (O 2 —) O—] as the natural nucleic acid. 1 or 2 or more of S-) O-] may be contained, and in the case of containing 2 or more of one or more of the above structures, Base may be the same or different between the structures.
- a DNA or RNA oligonucleotide analog containing the artificial nucleic acid BNA NC (NMe) which is a kind of the present invention has the following excellent characteristics. This is because the ability to form double strands for complementary RNA strands is very high.
- BNA NC (NMe) modified DNA oligonucleotides are extremely excellent in selective binding affinity to RNA strands.
- BNA NC (NMe) modified DNA oligonucleotides also excel in triplex forming ability for double-stranded DNA strands.
- the Tm value rises by 7 to 12 ° C. in triplex formation for a double-stranded DNA strand.
- sequence selectivity is required such that the base sequence is strictly identified and bound only to the target sequence, but the Tm against the match sequence and mismatch sequence of the BNA NC (NMe) modified DNA oligonucleotide.
- the difference in value is 25 ° C. or more, and the sequence selectivity is superior to that of the natural DNA oligonucleotide.
- nuclease resistance is outstanding.
- BNA NC (NMe) modified oligonucleotides are more nuclease resistant than natural DNA oligonucleotides, but much lower than S-oligos (phosphorothioate type oligonucleotides).
- the BNA NC (NMe) -modified oligonucleotide of the present invention is superior in nuclease resistance to SNA-oligo, which is highly evaluated for its excellent nuclease resistance, as well as BNA-modified oligonucleotides, and it can be degraded in vivo. It has a strong resistance characteristic.
- the N—O bond contained in the artificial nucleic acid BNA NC (NMe) molecule of the present invention can be selectively cleaved under a mild condition by a reducing reagent, and NH group and OH group are released. It is easy to obtain various complexes (conjugates) before and after the preparation of oligonucleotide analogues by binding other functional molecules based on these NH groups and OH groups.
- Other functional molecules include fluorescent molecules, chemiluminescent molecules, labeling molecules such as molecular species containing radioisotopes, various DNA (RNA) cleavage active molecules, intracellular and nuclear signal peptide, etc. It is.
- BNA NC (NMe) modified DNA and RNA oligonucleotide analogues modified in various forms are gene drugs by antisense method, antigene method, decoy method, gene homologous recombination method, RNA interference method, etc. Not only as a highly functional material created, but also as a base material for genetic diagnosis methods such as molecular beacons and DNA chips, and as a development material for research reagents for elucidating gene function analysis and the like, it is extremely useful.
- R 3 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkenyl group having 1 to 5 carbon atoms, carbon An aryl group of 6 to 14; a methyl group substituted with 1 to 3 aryl groups; a lower aliphatic or aromatic sulfonyl group such as a methanesulfonyl group or p-toluenesulfonyl group; or an acetyl group such as an acetyl group.
- Base is as described above, preferably an adenylyl group, thymine.
- the nucleoside analogs and oligonucleotide analogs of the present invention can be synthesized based on the methods described in the Examples and the prior art in the field.
- the compounds represented by the general formulas (BNA-1) and (BNA-2) can be synthesized based on the methods described in Examples and conventional techniques in this field.
- the reaction conditions, the protecting group introduction reagent, and the reaction reagent can be specifically referred to the methods described in the examples, but are not limited thereto, reaction conditions that can be used based on the common general technical knowledge in the field, Reagents can be employed as appropriate. For example, methods described in Japanese Patent Application Laid-Open Nos.
- Base is a nucleobase described herein, eg, adenine, guanine, cytosine, thymine, uracil.
- a suitable reagent eg 40% aqueous methylamine (0.11 ml, 1.50 mmol)
- a solution eg 3.5 ml THF solution
- a suitable temperature eg ice-cold
- an appropriate time eg 3 hours
- extraction is performed with a suitable organic solvent (for example, ethyl acetate), and the organic layer is washed (for example, with water and saturated brine).
- a suitable desiccant eg, anhydrous sodium sulfate
- reaction is quenched (for example, by adding water to the reaction solution), extracted with an appropriate organic solvent (for example, ethyl acetate), the organic layer is washed (for example, with saturated aqueous sodium bicarbonate and saturated brine), and then an appropriate drying agent (for example, it is dried with anhydrous sodium sulfate).
- an appropriate organic solvent for example, ethyl acetate
- the organic layer is washed (for example, with saturated aqueous sodium bicarbonate and saturated brine), and then an appropriate drying agent (for example, it is dried with anhydrous sodium sulfate).
- an appropriate drying agent for example, it is dried with anhydrous sodium sulfate.
- the solvent is distilled off under reduced pressure to obtain compound A-3.
- Compound A-3 can also be used in the next reaction without purification.
- the organic layer is washed (eg, with water, saturated saline) and then dried with a suitable desiccant (eg, anhydrous sodium sulfate).
- a suitable desiccant eg, anhydrous sodium sulfate.
- reaction solution is extracted with a suitable organic solvent (for example, ether), and the organic layer is washed (for example, with water and saturated brine) and then dried with a suitable desiccant (for example, magnesium sulfate).
- a suitable organic solvent for example, ether
- desiccant for example, magnesium sulfate
- a solution of compound A-7 (eg 0.29 g) (eg acetonitrile solution (3 ml)) at a suitable temperature (eg room temperature) (eg N-hydroxyphthalimide (67 mg, 0 .41 mmol), 1,8-diazabicyclo [5.4.0] -7-undecene (61 (1,0.41 mmol)) is added and stirred at an appropriate temperature (eg, room temperature) for an appropriate time (eg, 12 hours)
- the reaction solution is extracted with a suitable organic solvent (for example, dichloromethane), and the organic layer is washed (for example, with water and saturated brine) and then dried with a suitable desiccant (for example, anhydrous sodium sulfate).
- a suitable organic solvent for example, dichloromethane
- the resulting crude product is purified (for example, by silica gel column chromatography (chloroform)) to obtain compound A-7 ′.
- an appropriate reagent eg, hydrazine-hydrate (0.12 ml, 2.38 mmol
- the mixture is stirred for an appropriate time (for example, 10 minutes) at an appropriate temperature (for example, room temperature), and then the solvent of the reaction solution is distilled off, followed by filtration, and the filtrate is extracted with an appropriate organic solvent (for example, ethyl acetate).
- reaction is quenched (eg, with saturated aqueous sodium bicarbonate) and extracted with a suitable organic solvent (eg, ethyl acetate).
- a suitable organic solvent eg, ethyl acetate
- the organic layer is washed (eg with water, saturated saline) and dried over a suitable desiccant (eg magnesium sulfate).
- the step of removing OPG 4 and the step of crosslinking the 2′-position and the 4′-position may be the same step or different steps.
- a suitable organic solvent eg ethyl acetate
- the organic layer is washed (eg, with water, saturated saline) and then dried with a suitable desiccant (eg, anhydrous sodium sulfate).
- the amino group is substituted. Stir for an appropriate time (eg 1 hour).
- the reaction solution is extracted with a suitable organic solvent (for example, ethyl acetate), washed with (for example, water, saturated aqueous sodium hydrogen carbonate, saturated brine), and the organic layer is dried with a suitable desiccant (for example, anhydrous sodium sulfate).
- a suitable organic solvent for example, ethyl acetate
- washed with for example, water, saturated aqueous sodium hydrogen carbonate, saturated brine
- a suitable desiccant for example, anhydrous sodium sulfate
- BNA-3 The compound represented by the general formula BNA-3 can be synthesized based on the methods described in the Examples and the prior art in this field.
- the reaction conditions, the protecting group introduction reagent, and the reaction reagent can be specifically referred to the methods described in the examples, but are not limited thereto, reaction conditions that can be used based on the common general technical knowledge in the field, Reagents can be employed as appropriate.
- the method described in J. Org. Chem. 2010, 75, 1569-1581 can be referred to.
- J. Org. Chem. 2010, 75 The raw material of the compound of the present invention can be synthesized with reference to the method described in 1569-1581.
- PG 1 to PG 4 are independently protecting groups described herein, R 2 and R 2 ′ are substituents described herein, and Base is defined herein.
- An appropriate reagent for example, potassium carbonate
- a suitable temperature for example, under a nitrogen stream
- the reaction is quenched (eg, by adding water to the reaction solution), extracted with a suitable organic solvent (eg, ethyl acetate), and the organic layer is washed (eg, with saturated brine).
- the organic layer is dried with a suitable desiccant (for example, sodium sulfate), evaporated and then purified (for example, by silica gel column chromatography) to give compound B-2.
- a suitable desiccant for example, sodium sulfate
- Oligonucleotide analogs including the nucleoside analog of the present invention can be variously synthesized using a known DNA synthesizer. Then, the resulting oligonucleotide analog is purified using a reverse phase column, and the purity of the product is analyzed by reverse phase HPLC or MALDI-TOF-MS, thereby confirming the formation of a purified oligonucleotide analog.
- One or more nucleoside analogs of the present invention can be present in an oligonucleotide analog.
- oligonucleotide analog in which the nucleoside analog of the present invention is introduced in a required number (length) at a required position.
- the total length of the oligonucleotide analog is 2 to 50 nucleotide units, preferably 8 to 30 nucleotide units.
- the oligonucleotide analog of the present invention is hardly degraded by nuclease and can exist in the living body for a long time after administration to the living body. And, for example, it forms a duplex with sense RNA to inhibit transcription of in vivo components (proteins) that cause disease into mRNA. It is also thought to inhibit the growth of infected viruses.
- the oligonucleotide analogue of the present invention is expected to be useful as a medicine for treating diseases by inhibiting the action of genes such as antitumor agents and antiviral agents. That is, according to the present invention, there are oligonucleotide analogues and production intermediates thereof that have stable and excellent antisense or antigene activity, or excellent activity as a detection agent for a specific gene or a primer for initiation of amplification. Nucleoside analogs are provided.
- DNA and RNA oligonucleotide analogues obtained by modifying 2 ', 4'-BNANC monomer, which is one of the nucleoside analogues of the present invention, in various forms are various physiological and biologically active substances, Functional materials such as pharmaceutical materials, functional materials of double-stranded oligonucleotides for RNA interference and decoy methods, DNA chips that target single-stranded nucleic acids such as cDNA, molecular beacons, etc.
- Anti-sense methods including ribozymes and DNAzymes
- functional materials for anti-gene methods and gene homologous recombination methods materials for sensitive analysis of biological trace components by combination with fluorescent and luminescent substances, and gene function analysis It is useful as a development material for research reagents.
- nucleoside analogs and oligonucleotide analogs of the present invention can be formulated into parenteral preparations by incorporating conventional auxiliaries such as buffers and / or stabilizers. Further, as a topical preparation, a conventional pharmaceutical carrier can be blended to prepare an ointment, cream, solution, salve or the like.
- Oligonucleotides constituting S-TuD used in the present invention are synthesized by a synthesizer (eg, nS-8II synthesizer or AKTA oligopilot synthesizer).
- a synthesizer eg, nS-8II synthesizer or AKTA oligopilot synthesizer.
- a porous glassy solid support eg 2′-O-methyl-RNA CPG Link Technologies
- a 2′-O-methyl-RNA phosphoramidite with standard protecting groups eg Although not, 5′-O-dimethoxytrityl N6-benzoyladenosine-2′-O-methyl-3′-ON, N′-diisopropyl phosphoramidite, 5′-O-dimethoxytrityl-N4- Acetylcytidine-2'-O-methyl-3'-ON, N'-diisopropyl phosphoramidite, 5'-O-dimethoxytrityl-N2-isobutyrylguanosine-2'-O-methyl-3'- ON, N'-diisopropyl phosphoramidite, and 5'-O-dimethoxytrityluridine-2'-O-methyl-3'-ON, N'-diisopro Le phosphoramidite (all manufactured by Sigma-Aldrich
- phosphoramidites are used in a suitable solvent (eg acetonitrile (CH 3 CN)) at a suitable concentration (eg 0.1 M).
- a suitable solvent eg acetonitrile (CH 3 CN)
- a suitable concentration eg 0.1 M
- Appropriate ligation / reuse times eg 15 minutes
- the activator is, for example, but not limited to, 5-benzylmercapto-tetrazole (0.25M, manufactured by Wako Pure Chemical Industries), and the PO-oxidation is, for example, limited to this Although not iodine / water / pyridine is used.
- PS-thioation for example, but not limited to, commercially available sulfurization reagents for automated synthesizers of oligonucleotides (ie, EIDTH, DDTT, PADS, Beucage reagents, etc.) together with appropriate reagents (eg, pyridine). use.
- sulfurization reagents for automated synthesizers of oligonucleotides ie, EIDTH, DDTT, PADS, Beucage reagents, etc.
- appropriate reagents eg, pyridine
- the synthetic carrier is transferred to a suitable container (eg, a glass bottle).
- Oligonucleotide is used in an appropriate amount of time (eg 13 hours) at an appropriate temperature (eg 45 ° C.) using an equal mixture of 40% methylamine aqueous solution and 33% methylamine ethanol solution 15 mL per gram of carrier,
- the base and phosphate group are deprotected and cleaved from the support.
- the step of deprotecting the base and the step of deprotecting the phosphate group may be the same or different.
- the ethanol ammonia mixture is then filtered and placed in a suitable container (eg, a new 250 mL bottle).
- the carrier is washed (eg with 2 ⁇ 40 mL of ethanol / water (1: 1 v / v)). Thereafter, the solvent is removed by evaporation (for example using a rotary evaporator).
- Oligonucleotides are purified by HPLC (eg, reverse phase ion pair HPLC on a Source 15 RPC gel column).
- the buffer include, but are not limited to, 5% CH 3 CN, 0.1M triethylamine acetate buffer (pH 7.0) (buffer A) and 90% CH 3 CN, 0.1M triethylamine. This is an acetate buffer (pH 7.0) (buffer B).
- the oligonucleotide pool is then purified by HPLC (eg, Source 30Q anion pair HPLC).
- solutions and buffers include, but are not limited to, 0.6% trifluoroacetic acid (solution A), 20 mM sodium phosphate buffer (pH 7.5) (buffer C), and 20 mM phosphate. 2M sodium chloride (buffer D) in sodium buffer.
- solution A 0.6% trifluoroacetic acid
- buffer C 20 mM sodium phosphate buffer
- 2M sodium chloride buffer D
- fractions containing the full-length oligonucleotide are pooled, desalted and lyophilized.
- Compounds are finally analyzed on, for example, MALDI-TOF / MS and denaturing polyacrylamide gels.
- the concentration of the oligonucleotide is determined (for example, by measuring the absorbance using an ultraviolet spectrophotometer). Using the determined concentration, the complementary strands are mixed at an equimolar concentration, heated at an appropriate temperature (eg, 95 ° C.) for an appropriate time (eg, 10 minutes), and then gradually cooled to form a double strand. Double strand formation is confirmed, for example, by non-denaturing gel electrophoresis.
- the nucleic acid may contain a conjugate at the end.
- the conjugate include lipophilic substances, terpenes, protein binding substances, vitamins, carbohydrates, retinoids, peptides, and the like.
- the miRNA-inhibiting complex of the present invention can be designed to be composed of linear single-stranded nucleic acids (FIG. 31).
- the present invention is particularly concentrated on one side (right side in FIG. 31) of the double-stranded structure (stem I in FIG. 31) where all MBS is present, and each strand of the double-stranded structure is closed on that side.
- a complex in which both ends of a single-stranded RNA are on opposite sides of the double-stranded structure (FIG. 31).
- the sequence containing MBS may contain an additional double-stranded structure (eg, stem II or III in FIG. 31).
- the length of the single-stranded RNA may be determined as appropriate, for example, within 500 bases, preferably within 450 bases, within 420 bases, within 400 bases, within 380 bases, within 360 bases, within 340 bases, within 320 bases, within 300 bases, 300 bases Within base, within 280 base, within 260 base, within 240 base, within 220 base, within 200 base, within 180 base, within 160 base, within 140 base, within 120 base, within 100 base, or within 80 base.
- the length of a single-stranded RNA forming a complex having two double-stranded structures and two MBS is, for example, 60 to 300 bases, preferably 70 to 250 bases, 80 to 200 bases, 90 to 180 bases, Or 100 to 150 bases.
- the first double-stranded structure (double-stranded structure close to both ends of the single-stranded RNA) is, for example, 15-30 bp, preferably 16-28 bp, preferably 17-25 bp, preferably 17-24 bp, such as 17 bp, 18 bp.
- the second double stranded structure (an additional double stranded structure included in sequences containing MBS) to make the whole compact
- the length may be shorter than the length of the first double-stranded structure, for example, 4 bp to 20 bp, such as 5 bp to 15 bp, 5 bp to 12 bp, 5 bp to 10 bp, 6 bp to 9 bp, or 7 bp to 8 bp.
- the present invention also relates to RNA constituting the miRNA-inhibiting complex of the present invention (herein, RNA includes natural RNA and nucleic acid analogs) and includes RNA containing BNA.
- RNA includes natural RNA and nucleic acid analogs
- RNA containing BNA RNA containing BNA.
- the miRNA-inhibiting RNA complex is composed of one molecule of RNA, by annealing the RNA within the molecule, or when composed of two or more RNA molecules, annealing those RNAs.
- the complex of the present invention can be constructed. These RNAs can be appropriately synthesized. For example, desired RNA can be produced by chemical synthesis of RNA.
- a nucleic acid encoding at least one MBS may contain more than one MBS, and may contain a set of one or more complementary sequences that can form a double-stranded structure in a stretch of sequences.
- examples of the nucleic acid include a pair of complementary sequences forming at least one double-stranded structure and a nucleic acid containing at least one MBS at both ends of the pair of complementary sequences.
- such a nucleic acid is a nucleic acid containing a pair of complementary sequences capable of forming a stem between two MBS. This stem corresponds to the second double-stranded structure.
- a sequence that forms a G-quadruplex may be included instead of the second double-stranded structure.
- the nucleic acid may contain two or more structural units including a pair of complementary sequences that can form a double-stranded structure between two MBS.
- the structural unit can be included in multiple nesting structures, and between a pair of complementary sequences that can form a double-stranded structure between a pair of MBS, and another pair of MBS and a double-stranded structure between them.
- a sequence including a pair of complementary sequences that can form (such as # 15 and # 16 in FIG. 31) can be included.
- Multiple MBS sequences may be the same or different.
- MBS a sequence forming a second double-stranded structure—is between a pair of complementary sequences forming a first double-stranded structure—
- a nucleic acid having a structure in which a sequence having an MBS structure is inserted is obtained.
- MBS a pair of complementary sequences forming a second double-stranded structure—a nucleic acid having a structure in which a sequence having the MBS structure is inserted.
- a nucleic acid consisting of two double-stranded structures and a pair of opposing single strands (each containing MBS) is compact and exhibits sufficient miRNA inhibitory activity.
- a pair of complementary sequences capable of forming a double-stranded structure and MBS can be appropriately linked via a linker or spacer.
- the length of the linker or spacer is as described in the specification.
- complementary sequences may be linked via a linker or spacer.
- the linker or spacer becomes a loop, and the double strand is combined to form a stem loop.
- the length of the loop may be appropriately adjusted, and details are as described in the specification.
- a sequence forming a G-quadruplex can be appropriately used instead of the double strand.
- the present invention is a miRNA inhibition complex comprising RNA or an analog thereof, wherein the miRNA inhibition complex comprises at least one double-stranded structure and a miRNA binding sequence, wherein the miRNA binding sequence Provided is a miRNA-inhibiting complex, wherein two strands are bound one by one to at least one strand of the double-stranded structure, and the miRNA-inhibiting complex comprises at least one cross-linked nucleic acid (BNA) .
- BNA cross-linked nucleic acid
- Such a complex is also called S-TuD
- the present invention is a further improvement of this complex, and is also called improved S-TuD or modified S-TuD.
- This improved S-TuD contains at least one cross-linked nucleic acid (BNA).
- BNA cross-linked nucleic acid
- the BNA is at least selected from the group consisting of carbon, carbon and nitrogen on the 4 ′ position via at least one atom selected from the group consisting of oxygen and carbon on the 2 ′ position.
- the BNA used in the present invention is
- R 1 , R 1 ′, R 2 , R 2 ′ and R 3 each independently represents a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, an aralkyl group, an acyl group, A group selected from the group consisting of a sulfonyl group, a silyl group, and a functional molecular unit substituent, m is an integer of 0 to 2, and Base is an adenylyl group, a thyminyl group, a urasilyl group, an inosinyl group, A cytosynyl group, a guaninyl group, a methylcytosynyl group or a derivative thereof, wherein n is an integer of 1 to 3 and q is an integer of 0 or 1. .
- the BNA used in the present invention is
- R 3 is selected from the group consisting of a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group, an aralkyl group, an acyl group, a sulfonyl group, a silyl group, and a functional molecular unit substituent.
- Base represents an adenynyl group, a thyminyl group, a urasilyl group, an inosinyl group, a cytosynyl group, a guaninyl group, a methylcytosynyl group or a derivative thereof, m is an integer of 0 to 2, and n is an integer of 1 to 2 ', 4'-substituted cross-linked nucleic acid represented by 3).
- the BNA used in the present invention is
- LNA 2 ', 4' methano-bridged nucleic acid
- BNA NC (NMe) is particularly preferable. Although not wishing to be bound by theory, using this particular nucleic acid increased stability, promoted duplex formation, and further improved biological activity was observed.
- cEt can be used.
- BNA (cEt) has the same thermal stability and mismatch discrimination as conventional LNA, but improves stability against nucleases.
- the BNA used in the present invention is contained in at least one strand of the double-stranded structure moiety and at least one strand of the complementary strand of the miRNA binding sequence.
- the BNA used in the present invention is contained in at least one chain of the double-stranded structure moiety. In another embodiment, the BNA used in the present invention is included in both strands of the double stranded structural moiety.
- the complex of the present invention may include one or more “double-stranded structures” or a plurality of “double-stranded structures”, and may have an S-TuD structure similar to that in Patent Document 1 or the examples.
- a double-stranded structure is in series, three or four can be included in succession, and it is understood that such embodiments are also included in the present invention.
- the complex of the present invention comprises two or more of the double-stranded structures, and a strand comprising a miRNA binding sequence in two strands at one end of the first double-stranded structure of the double-stranded structure.
- a strand comprising a miRNA binding sequence in two strands at one end of the first double-stranded structure of the double-stranded structure are connected to each other, and the other end of each of the strands is a second duplex of the two or more double-stranded structures, so that each of the strands is sandwiched between the two or more double-stranded structures.
- Each is bound to two strands of the structure.
- the ends of two strands containing miRNA binding sequences are bound to two strands at one end of the double-stranded structure one by one through a linker of 1 to 5 bases each.
- each of the two strands is bonded to two strands at one end of the second multi-stranded structure via a linker of 1 to 5 bases, but the present invention is not limited to this.
- the two strands comprising the miRNA binding sequence included in the complex of the present invention each strand comprising an miRNA binding sequence and two strands comprising the miRNA binding sequence, Is not limited to this.
- the ends of two strands containing a miRNA binding sequence are linked via a linker.
- the linker has a length of 1 to 10 bases, more preferably 1 to 9 bases, further preferably 1 to 8 bases, and more preferably The length is 1 to 7 bases, more preferably 1 to 5 bases, and may be 4 bases, 3 bases, 2 bases, 1 bases.
- the length of the double-stranded structure in the miRNA inhibition complex of the present invention may be any length as described above, but preferably has a length of 4 base pairs or more.
- at least one of the double-stranded structures included in the RNA complex of the present invention (that is, the first double-stranded structure) has an important function for nuclear export of the RNA complex.
- the length of this double strand may be, for example, 10 to 50, 15 to 50 base pairs, and preferably 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45 bases, Or any one or more thereof, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, or 18 bases, or any of them.
- the length of the base pair of the double-stranded structure is, for example, 10-30, 15-30, preferably 16-28, preferably 17-25, preferably 17-24, such as 17, 18, 19 , 20, 21, 22, 23, or 24.
- dsRNA exceeding 20 bp can be a potential target for cleavage by Dicer in the cytoplasm, so it is included in the complex of the present invention to avoid it.
- the double-stranded structure can be 20 bp or less, such as 19 bp or less, or 18 bp or less.
- the double-stranded structure contained in the miRNA inhibition complex is further described in the following preferred embodiments.
- 5 bp to 15 bp, 5 bp to 12 bp, 5 bp to 10 bp, 6 bp to 9 bp, 7 bp to 8 bp, 10 bp to 12 bp may be used.
- the lower limit length of the double-stranded structure in the complex of the present invention is not particularly limited as long as the activity is maintained, but it is at least 4 bases long, at least 5 bases long, at least 6 bases long, at least 7 bases Long, at least 8 bases long, preferably at least 9 bases long, more preferably at least 10 bases long.
- their base lengths may be the same or different.
- it has been confirmed that sufficient formation of a double strand is confirmed with a length of 10 bases and has a sufficient effect, but in some cases, for example, at least 11 bases, at least 12 bases, at least 13 bases , At least 14 bases long, at least 15 bases long, at least 16 bases long, at least 17 bases long, at least 18 bases long.
- the upper limit length of the double-stranded structure in the complex of the present invention is not particularly limited as long as the activity is maintained.
- the length is 100 bases or less, 90 bases or less, 80 bases or less, 70
- the length may be not more than the base length, not more than 60 base length, not more than 50 base length, and the like.
- the miRNA-inhibiting complex of the present invention contains a second or more double-stranded structure
- these double-stranded structures may be shorter than the length of the first double-stranded structure, for example, in order to make the entire miRNA inhibition complex compact.
- the length of each double strand may be adjusted as appropriate, and is, for example, 4 bp to 20 bp, for example, 5 bp to 15 bp, 5 bp to 12 bp, 5 bp to 10 bp, 6 bp to 9 bp, or 7 bp to 8 bp.
- the effect is expected to be obtained, but preferably 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more. More than 9, more than 9, more than 10 may be included. However, there are cases where about 6 pieces have a sufficient effect, and there are cases where the effect does not increase even if it is included more than that, it may be sufficient to include about 6 pieces (for example, 4-8 pieces, 4-6 pieces, etc.). .
- the complex of the present invention has a stronger activity (acts at a low concentration) than the conventional complex.
- the complex of the present invention is about 2 times or more, about 3 times or more, about 4 times or more, about 5 times or more, about 6 times or more, about 7 times that of the conventional complex.
- the complex of the present invention acts at 10 nM or less, acts at 5 nM or less, acts at 3 nM or less, acts at 1 nM or less, acts at 500 pM or less, acts at 300 pM or less, and at 100 pM or less.
- the complex of the invention comprises 2 to 5 miRNA binding sequences, preferably 2 miRNA binding sequences.
- the complex of the present invention is
- I and II of the structure are double stranded structures, and can take a structure containing one miRNA binding sequence in each of a and b of the structure.
- the present invention provides each RNA or analog thereof (ie, each single strand) constituting the complex of the present invention, and each of these RNAs or analogs thereof is also of the present invention. Is in range. Preferred embodiments in the case of single strands are substantially the same as in the double stranded structure, and similar preferred embodiments can be employed.
- the present invention provides a method for producing the complex of the present invention, comprising: A) protecting a single strand of RNA of interest or an analog thereof using ribonucleic acid and BNA by chemical synthesis. A step of synthesizing the body and its complement; B) a step of deprotecting the produced single-stranded protector and its complement respectively; and C) two steps of each of the deprotected single strands.
- a method comprising the step of forming a duplex by placing it in a chain forming condition.
- the present invention is a method for producing the RNA of the present invention or an analog thereof, comprising A) a single strand of the RNA of interest or an analog thereof using ribonucleic acid and BNA by chemical synthesis. And B) deprotecting each of the produced single-stranded protector and its complement, respectively.
- the present invention provides a medicament comprising the complex of the present invention.
- the miRNA-inhibiting complex of the present invention is a composition for inhibiting miRNA, Since the composition of the present invention can specifically and efficiently inhibit a target miRNA, the composition of the present invention is useful for controlling the function of a gene through inhibition of miRNA.
- RNA includes natural RNA and analogs
- the composition of the present invention is useful for controlling the function of a gene through inhibition of miRNA.
- any desired pharmacologically acceptable carrier or vehicle including the desired solutions normally used for suspending nucleic acids, such as distilled water, phosphate buffered saline (PBS). ), Sodium chloride solution, Ringer's solution, culture solution, etc. It may also contain vegetable oils, suspending agents, surfactants, stabilizers, biocides, etc.
- composition of the invention can also be combined with organic substances such as biopolymers, inorganic substances such as hydroxyapatite, specifically collagen matrices, polylactic acid polymers or copolymers, polyethylene glycol polymers or copolymers and chemical derivatives thereof as carriers.
- the composition of the present invention can be used as a desired reagent or as a pharmaceutical composition, and the present invention also includes the composition of the present invention, the miRNA-inhibiting complex of the present invention, or the RNA constituting the complex or an analog thereof.
- the use of the body to inhibit miRNA is also provided, and the present invention provides miRNA inhibitors comprising any of them.
- the present invention provides a method of treating or preventing a disease or disorder comprising the step of administering an effective amount of a complex of the present invention or a medicament comprising the same to a subject in need thereof.
- the present invention is not limited, but can be applied to, for example, use as an HCV therapeutic agent or a renal fibrosis therapeutic agent that has already been clinically developed.
- the medicament of the present invention may be administered per se, or may be administered as an appropriate pharmaceutical composition.
- the pharmaceutical composition used for administration may contain the medicament of the present invention and a pharmacologically acceptable carrier, diluent or excipient.
- Such pharmaceutical compositions are provided as dosage forms suitable for oral or parenteral administration.
- injections are dosage forms such as intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, infusions, and the like. May be included.
- Such an injection can be prepared according to a known method.
- a method for preparing an injection it can be prepared, for example, by dissolving, suspending or emulsifying the nucleic acid of the present invention in a sterile aqueous liquid or oily liquid usually used for injection.
- an aqueous solution for injection for example, an isotonic solution containing physiological saline, glucose and other adjuvants, and the like are used, and suitable solubilizers such as alcohol (eg, ethanol), polyalcohol (eg, Propylene glycol, polyethylene glycol), nonionic surfactants (eg, polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castoroil)) May be.
- alcohol eg, ethanol
- polyalcohol eg, Propylene glycol, polyethylene glycol
- nonionic surfactants eg, polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castoroil)
- oily liquid for example, sesame oil, soybean oil and the like are used, and benzyl benzoate, benzyl alcohol and the like may be used in combination as a solubilizing agent.
- the prepared injection solution is preferably filled in
- compositions for oral administration include solid or liquid dosage forms, specifically tablets (including dragees and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups Agents, emulsions, suspensions and the like.
- Such a composition is produced by a known method and may contain a carrier, a diluent or an excipient usually used in the pharmaceutical field.
- a carrier and excipient for tablets for example, lactose, starch, sucrose, and magnesium stearate are used.
- the above parenteral or oral pharmaceutical composition is conveniently prepared in a dosage unit form suitable for the dose of the active ingredient.
- dosage form of such a dosage unit include tablets, pills, capsules, injections (ampoules), and suppositories.
- the medicament of the present invention has low toxicity and can be used as it is as a liquid or as a pharmaceutical composition of an appropriate dosage form for humans or mammals (eg, rats, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, etc.). It can be administered orally or parenterally (eg, intravascular administration, subcutaneous administration, etc.).
- humans or mammals eg, rats, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, etc.
- parenterally eg, intravascular administration, subcutaneous administration, etc.
- Introduction into cells can be performed in vitro, ex vivo or in vivo.
- the cells When administered via cells, the cells are introduced into appropriate cultured cells or cells collected from the inoculated animal.
- Examples of the introduction of nucleic acid include calcium phosphate coprecipitation method, lipofection, DEAE dextran method, a method of directly injecting a DNA solution into a tissue by an injection needle or the like, and introduction by a gene gun.
- the dose varies depending on the disease, patient weight, age, sex, symptoms, administration purpose, administration composition form, administration method, transgene, etc., but it is adjusted appropriately according to the animal to be administered, administration site, administration frequency, etc. It can be determined appropriately by those skilled in the art.
- the administration route can be appropriately selected.
- the administration subject is preferably a mammal (including human and non-human mammals). Specifically, non-human primates such as humans and monkeys, rodents such as mice and rats, rabbits, goats, sheep, pigs, cows, dogs, cats, and other mammals are included.
- the nucleoside analog and the oligonucleotide analog of the present invention were synthesized according to the following synthesis scheme. These syntheses are described in more detail in the examples. In addition, the properties of the synthesized oligonucleotide analogues were measured by experimental examples.
- Long Type refers to the same STEM left 18 bp, right 10 bp as the original S-TuD (SEQ ID NOS: 1-2), and Short type refers to STEM left 10 bp, right 10 bp. Refers to things.
- Oligonucleotides were synthesized with an nS-8II synthesizer or an AKTA oligopilot synthesizer.
- Commercially available pore glassy solid phase support (2'-O-methyl-RNA CPG Link Technologies) and 2'-O-methyl-RNA phosphoramidite with standard protecting groups, ie 5'- O-dimethoxytrityl N6-benzoyladenosine-2'-O-methyl-3'-ON, N'-diisopropyl phosphoramidite, 5'-O-dimethoxytrityl-N4-acetylcytidine-2'-O-methyl -3'-O-N, N'-diisopropylphosphoramidite, 5'-O-dimethoxytrityl-N2-isobutyrylguanosine-2'-O-methyl-3'-O-N, N'-diisopropylphosphoramidite, 5'-O-dimethoxytrityl
- phosphoramidites were used in acetonitrile (CH 3 CN) at a concentration of 0.1M.
- CH 3 CN acetonitrile
- BNA and LNA a 15 minute ligation / reuse time was used.
- the activator was 5-benzylmercapto-tetrazole (0.25M, manufactured by Wako Pure Chemical Industries, Ltd.), and iodine / water / pyridine was used for PO-oxidation.
- PS-phosphorothioation commercially available sulfurizing reagents for automated oligonucleotide synthesizers (ie, EIDTH, DDTT, PADS, Beucage reagents, etc.) were used with pyridine.
- Oligonucleotides were purified by reverse phase ion pair HPLC on a Source 15 RPC gel column. Buffers are 5% CH 3 CN, 0.1 M triethylamine acetate buffer (pH 7.0) (buffer A) and 90% CH 3 CN, 0.1 M triethylamine acetate buffer (pH 7.0) (buffer B). there were. Fractions containing the full length oligonucleotide with the dimethoxytrityl group retained at the 5 ′ end were pooled and subjected to the next purification. The oligonucleotide pool was then purified by Source30Q anion pair HPLC.
- the solution and buffer consisted of 0.6% trifluoroacetic acid (solution A), 20 mM sodium phosphate buffer (pH 7.5) (buffer C) and 2 M sodium chloride (buffer) in 20 mM sodium phosphate buffer. D). After removing the dimethoxytrityl group using solution A, fractions containing the full-length oligonucleotide were pooled, desalted and lyophilized. The compounds were finally analyzed on MALDI-TOF / MS and denaturing polyacrylamide gels.
- HeLaS3 cells were plated at 1x10 5 cells per well in 6-well plates (1x10 5 cells per well), pLSP-miR199a viral vector after 24 hours ( ⁇ 1x10 4 TU), were introduced in the presence of polybrene 8 [mu] g / ml From 24 hours after the transduction, puromycin (1 ug / ml) was selected. After selection for one week, puromycin was removed from the medium, and HeLaS3-miR199a cells were obtained as HeLaS3 cells carrying the miR-199a reporter.
- GLOMAX TM Promega
- Example 1 Structural strengthening test
- the miRNA inhibitor developed by the present inventors is attracting attention as a nucleic acid that inhibits miRNA activity at low concentrations, but its physical properties after being double-stranded due to its structural characteristics Is not stable. Therefore, in this example, in order to facilitate the stable mass production of S-TuD and the establishment of a physical property test method, a modification that improves the hybridization ability of the double-stranded region is a method for strengthening the double-stranded region.
- a nucleic acid partially substituted with nucleic acid was used, and miRNA inhibitory activity was compared with conventional S-TuD (FIG. 1A).
- FIG. 1B shows the result of reversed-phase HPLC analysis with conventional S-TuD.
- FIG. 1B shows a comparison of S, AS, and double strands analyzed by reverse-phase HPLC (RP-HPLC) analysis of conventional S-TuD (C18 reverse-phase ion-pair HPLC, XBridge column).
- RP-HPLC reverse-phase HPLC
- 2′-O-methyl RNA was used for the basic structure of S-TuD, and BNA NC (NMe) was used as a modified nucleic acid.
- BNA NC NMe
- the LNA can be used similarly.
- the structure of the oligonucleotide used is shown in FIGS. 2A and 2B.
- the synthesized oligonucleotide was used.
- both the 2'-O-methyl body as in the original S-TuD as shown in FIG. 39-1, FIG. 39-2 and FIG. While some strands remained as single strands, substitution with BNA improved the ability to form double strands.
- the protocol for miR-199a inhibition assay is as follows.
- the activity of the target miRNA was measured by taking the ratio of Renilla luciferase (RL) and firefly luciferase (FL).
- HeLaS3 cells (Landgraf, P. et al. (2007) Cell, 129, 1401-1414) that express miR199a_3p and 5p endogenously only slightly and DMEM containing 10% fetal bovine serum (FBS) Medium was cultured at 37 ° C.
- HeLaS3 cells were plated at 1x10 5 cells per well in 6-well plates (1x10 5 cells per well), 24 hours after pLSP-miR199a viral vector ( ⁇ 1x104 TU), were introduced in the presence of polybrene 8 [mu] g / ml, Selection was made with puromycin (1 ug / ml) from 24 hours after transduction. After selection for one week, puromycin was removed from the medium, and HeLaS3-miR199a cells were obtained as HeLaS3 cells carrying the miR-199a reporter.
- FBS fetal bovine serum
- the miRNA inhibition activity was further improved by modifying the MBS region.
- the length of the STEM region was the same as the original, and part of the STEM region was replaced with BNA NC (NMe). This indicates that improvement in physical properties has a positive effect on the activity itself.
- BNA NC NMe
- STEM region shortened S-TuD having the same activity can be achieved, and the cost can be reduced.
- Example 2 Replacement with MBS region
- BNA NC NMe
- FIGS. 8-1 and 8-2 The results obtained by substituting a part of the MBS region with BNA NC (NMe) for the structure obtained in this example are shown in FIGS. 8-1 and 8-2. As shown in FIG. 8-1 and FIG. 8-2, it was possible to obtain a structure in which the inhibitory activity was improved up to about 10 times compared to the original S-TuD. It was important to insert a part of BNA into the non-seed region of MBS region.
- the original ( The effect was about 10 times lower than that of Long type (unmodified).
- S-TuD having a STEM I region shortened to a minimum of 10 mer, in which a part of the STEM region is replaced with BNA further enhances the effect.
- S-TuD partially substituted with BNA in the miS non-seed region of MBS has the same effect.
- the stability in serum was improved compared to the conventional S-TuD of the present invention. Therefore, since the S-TuD of the present invention can be provided as a stable pharmaceutical, it is used as a therapeutic agent when miRNA overexpression causes pathogenesis, and of course, as a miRNA-related research reagent. It is expected that it can be utilized.
- Example 3 STEM region shortening + confirmation of BNA insertion effect in MBS region
- S-TuD (Structure used) The structure of S-TuD used in this example is shown in FIG. Original sequence of S-TuD199a-3p, (16) S-TuD-miR-199a-3p-1_18-pf-L18B6-2, (1) 'S-TuD199a-3p-1_18-pf-S10, (6)' S-TuD199a-3p-1_18-pf-S10-BT6, (17) S-TuD199a-3p-1_18-pf-S10-BT6-MBSB1 (complementary sequence of the seed region into BNA NC (NMe)), (18) S-TuD199a-3p-1_18-pf-S10-BT6-MBSB2 (complementary sequence of non-seed region was converted to BNA NC (NMe)) was used.
- FIGS. 11-1 and 11-2 The results for individual S-TuD 100 pM and 300 pM are shown in FIGS. 11-1 and 11-2.
- FIGS. 11A and 11B the effect of BNA modification was examined on the short type.
- the original and long type Stem-BNA modifications (16) were added for comparison.
- Short type-BNA unmodified (1) ' the effect of (6)' with BNA modification in the stem part was greatly enhanced.
- BNA modification at the Seed equivalent site (17) did not enhance the effect.
- the BNA modification was added to the non-seed equivalent site (18)
- the effect was further enhanced and became equal to or higher than (16). It was found that the short type has an enhancing effect depending on the BNA modification site in MBS.
- Example 4 stability in serum
- stability in serum was confirmed using mouse serum.
- FIGS. 12 to 13 The structure of the modified S-TuD used is shown in FIGS. 12 to 13 and FIG. That is, the original structure, (16) S-TuD-miR-199a-3p-1_18-pf-L18B6-2, (23) S-TuD-miR-199a-3p-1_18-pf-L18B6-2-MBSB2 (non- BNA complementary sequence of seed region NC (NMe) of), (23) - (1 ) S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS1 (the complementary sequence of the non-seed region BNA NC (NMe)), (23)-(2) S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS2 (complementary sequence of non-seed region is converted to BNA NC (NMe)) and (23 )-(3) S-TuD-miR-199a-3p-1_18-pf-L18B6-2
- the short type S-TuD was considerably degraded without modification, but showed some nuclease resistance.
- the Stem part was modified with BNA, complete resistance was obtained. Even if MBS-BNA modification was further added here, no further effect was observed.
- the BNA NC (NMe) substitution of S-TuD-200c-1_22-pf is improved in serum stability as in the case of S-TuD199a. I was able to confirm.
- Example 5 Experiment of universality
- the same kind of experiment was conducted targeting two types of miRNAs.
- the assay method is the same as in Example 1 except that the construct used in the reporter assay is replaced with miR-200c and miR-21.
- miR-200c The structure for miR-200c is shown in FIG.
- the structure for miR-21 is shown in FIG.
- miR-200c includes (41) S-TuD-200c-1_22-pf, (42) S-TuD-200c-1_22-pf-L18B6, (43) S-TuD-200c-1_22-pf-L18B6-MBSB1 ( BNA complementary sequence of seed region NC (NMe) of), (44) S-TuD -200c-1_22-pf-L18B6-MBSB2 (BNA complementary sequence of the non-seed region NC (NMe) of), (45) S -TuD-200c-1_22-pf-S10-BT6-MBSB2 (complementary sequence of non-seed region was converted to BNA NC (NMe)) was used.
- miR-21 includes (51) S-TuD-21-1_17-10mut, (52) S-TuD-21-1_17-10mut-L18B6, (53) S-TuD-21-1_17-10mut-L18B6-MBSB1 (54) S-TuD-21-1_17-10mut-S10-BT6 and (55) S-TuD-21-1_17-10mut-S10-BT6-MBSB1 were used.
- FIG. 20 shows the results of electrophoresis showing serum resistance.
- FIGS. 21-1 and 21-2 show the results of the reporter assay.
- the target miR-199a increased the inhibitory activity by about 10 times
- the target miR-200c increased by about 2 times.
- FIGS. FIG. 24 shows an electropherogram after treatment with mouse serum.
- the main band did not appear in the unmodified long type (51), and smear was observed.
- the modified S-TuD (52-55) showed a clear main band, confirming the improvement in serum stability. In all the results, it is considered that the band clearly appears at the upper part of the main band is non-specific binding with serum protein.
- a graph of the reporter assay results with miR-21 is shown in FIGS. 25-1 and 25-2 (miR-21). Compared to S-TuD21 (Original; 51), the stem portion was modified with BNA NC (NMe) (52).
- both the long type and the short type be modified with BNA NC (NMe) modification in both the Stem part and the non-seed equivalent part of MBS in terms of both effect and stability.
- BNA NC (NMe) conversion of the stem part is considered desirable.
- the degree of the effect of BNA NC (NMe) at the non-seed equivalent site of Long type MBS varies greatly depending on the type of miRNA.
- stem length in vitro results, long type seemed to be slightly more effective than short type.
- Example 6 In vivo experiment
- miR-122 inhibitor LNA-ASO
- PII miR-122 inhibitor
- the miR-21 inhibitor (LNA-ASO) included in this study has been completed by non-clinical studies and Phase I as a therapeutic agent that suppresses renal fibrosis by Regulus, and is currently progressing to Phase II. From the above, the results of this example should be evaluated as in vivo data indicating that the S-TuD of the present invention can be used as a medicine.
- Example 7 Comparative test of various cross-linked nucleic acids
- the S-TuD basic structure is a 10-MBS-10 type with STEM I trimmed to 10 bp (indicated by (5)).
- As the assay method the same technique as the miR199a luciferase reporter assay used in Example 1 and the like was used.
- Example 8 STEM region shortening test
- the same technique as the miR199a luciferase reporter assay used in Example 1 and the like was used.
- Example 9 Activity correlation test between STEM region shortening and cross-linked nucleic acid substitution
- the combination of STEM region shortening and cross-linked nucleic acid substitution was performed using the original S-TuD (STEM I18bp STEM II 10bp).
- the structure of the sequence used is shown in FIG.
- the assay method the same method as the miR199a luciferase reporter assay shown in Example 1 and the like was used.
- FIGS. 37-1 and 37-2 The results are shown in FIGS. 37-1 and 37-2.
- the miRNA inhibitory activity of S-TuD is 1 when the original is 1, S-TuD with BNA substitution in STEM I and II of the original S-TuD is more than 3 times, STEM I is shortened to 10 bp and BNA NC ( NMe) Substituted S-TuD improved activity about 3 times. This indicates that strengthening STEM duplex formation plays a major role in miRNA inhibitory activity of S-TuD.
- the present invention is useful in the pharmaceutical industry and the reagent industry using nucleic acid drugs and the like.
- SEQ ID NO: 1 Original sense sequence of FIG. 2A (same for FIG. 4-1)
- SEQ ID NO: 2 Original antisense sequence of FIG. 2A
- SEQ ID NO: 3 Sense sequence of FIG. 2A (1)
- SEQ ID NO: 4 Antisense sequence of FIG. 2A (1)
- SEQ ID NO: 5 Sense sequence of SEQ ID NO: 2A
- 6 antisense sequence of FIG. 2A
- SEQ ID NO: 7 sense sequence of FIG. 2A
- SEQ ID NO: 8 antisense sequence of FIG. 2A
- SEQ ID NO: 9 sense sequence of SEQ ID NO: 2A (4)
- 10 antisense sequence SEQ ID NO: 11 in FIG. 2A (4): sense sequence SEQ ID NO: 12 in FIG.
- Sense sequence SEQ ID NO: 24 antisense sequence SEQ ID NO: 25 in FIG. 7 (18): Sense sequence SEQ ID NO: 26 in FIG. 7 (23)-(1): Antisense sequence SEQ ID NO: in FIG. 7 (23)-(1) 27: Sense sequence SEQ ID NO: 28 in FIGS. 7 (23)-(2): Antisense sequence SEQ ID NO: 29 in FIGS. 7 (23)-(2): Sense sequence SEQ ID NO: 30 in FIGS. 7 (23)-(3) : Antisense sequence of FIG. 7 (23)-(3) SEQ ID NO: 31: sense sequence of FIG. 10 (1) ′ SEQ ID NO: 32: antisense sequence of FIG. 10 (1) ′ SEQ ID NO: 33: FIG.
- Sense sequence SEQ ID NO: 46 FIG. 19 (45) antisense sequence SEQ ID NO: 47: FIG. 23 (51) sense sequence SEQ ID NO: 48: FIG. 23 (51) antisense sequence SEQ ID NO: 49: FIG. 23 (52) ) Sense sequence SEQ ID NO: 50: antisense sequence SEQ ID NO: 51 in FIG. 23 (52): sense sequence SEQ ID NO: 52 in FIG. 23 (53): antisense sequence SEQ ID NO: 53 in FIG. 23 (53) ) Sense sequence SEQ ID NO: 54: antisense sequence SEQ ID NO: 5 of FIG. 23 (54) : Sense sequence of Fig. 23 (55) SEQ ID NO: 56: antisense sequence of Fig.
- SEQ ID NO: 57 sense sequence of S-TuD NC2 (Figs. 18 and 22)
- SEQ ID NO: 58 S-TuD NC2 (Fig. 18, FIG. 22) antisense sequence
- Antisense sequence SEQ ID NO: 75: psiCHECK2-T200c-3p-s (sense sequence) in FIG. SEQ ID NO: 76: psiCHECK2-T200c-3p-a (antisense sequence) of FIG. SEQ ID NO: 77: psiCHECK2-T199a-3px3-s of FIG. 17 (sense sequence) SEQ ID NO: 78: psiCHECK2-T199a-3px3-a of FIG. 17 (antisense sequence) SEQ ID NO: 79: psiCHECK2-T21-5p-s (sense sequence) in FIG. SEQ ID NO: 80: psiCHECK2-T21-5p-a (antisense sequence) of FIG.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
さらに最近本発明者らの一部は、miRNAを効率的に阻害するためのmiRNA阻害体、該阻害体を細胞内で発現させるためのベクター、該ベクターの構築方法、および該阻害体またはベクターを利用したmiRNAの阻害方法を開発した(特許第4936343号公報=特許文献1)。
(1)RNAまたはその類縁体を含むmiRNA阻害複合体であって、該miRNA阻害複合体は、少なくとも1つの二本鎖構造およびmiRNA結合配列を含み、該miRNA結合配列の2つの鎖が、該二本鎖構造の少なくとも片端の2つの鎖に一本ずつ結合しており、該miRNA阻害複合体は少なくとも1つの架橋核酸(BNA)を含む、miRNA阻害複合体。
(2)前記BNAは2’位側で酸素および炭素からなる群より選択される少なくとも1つの原子を介し、4’位側で炭素と炭素および窒素からなる群より選択される少なくとも1つ原子を介して架橋されたBNAを含む、項目1に記載の複合体。
(3)前記BNAは
(4)前記BNAは、
(5)前記BNAは、
(6)前記BNAはBNANC(NMe)である、項目1~5のいずれか一項に記載の複合体。
(7)前記BNAは、前記二本鎖構造部分の少なくとも一方の鎖および前記miRNA結合配列の相補鎖の少なくとも一つの鎖に含まれる、項目1~6のいずれか一項に記載の複合体。
(8)前記BNAは、前記二本鎖構造部分の少なくとも一方の鎖に含まれる、項目1~7のいずれか一項に記載の複合体。
(9)前記BNAは、前記二本鎖構造部分の両方の鎖に含まれる、項目1~8のいずれか一項に記載の複合体。
(10)前記BNAは2つ以上含まれる、項目1~9のいずれか一項に記載の複合体。
(11)前記BNAは4つ以上含まれる、項目1~10のいずれか一項に記載の複合体。
(12)前記BNAは6つ以上含まれる、項目1~11のいずれか一項に記載の複合体。
(13)前記複合体は、前記二本鎖構造を2つ以上含み、該二本鎖構造の第1の二本鎖構造の片端の2つの鎖にmiRNA結合配列を含む鎖がそれぞれ1本ずつ結合しており、該2つ以上の二本鎖構造に挟まれるように、該鎖のそれぞれの他端が、該2つ以上の二本鎖構造の第2の二本鎖構造の2つの鎖にそれぞれ結合している、項目1~12のいずれか一項に記載の複合体。
(14)前記miRNA結合配列を含む2つの鎖の末端が、リンカーを介して結合している、項目1~13のいずれか一項に記載の複合体。
(15)前記リンカーの長さは1~5塩基長である、項目14に記載の複合体。
(16)前記二本鎖の構造は、少なくとも6塩基長である、項目1~15のいずれか一項に記載の複合体。
(17)前記二本鎖の構造は、少なくとも8塩基長である、項目1~16のいずれか一項に記載の複合体。
(18)前記二本鎖の構造は、少なくとも10塩基長である、項目1~17のいずれか一項に記載の複合体。
(19)前記二本鎖の構造は、少なくとも15塩基長である、項目1~18のいずれか一項に記載の複合体。
(20)前記二本鎖の構造は、少なくとも18塩基長である、項目1~19のいずれか一項に記載の複合体。
(21)前記二本鎖の構造は、50塩基長以下である、項目1~20のいずれか一項に記載の複合体。
(22)2から5つのmiRNA結合配列を含む、項目1~21のいずれか一項に記載の複合体。
(23)2つのmiRNA結合配列を含む、項目1~22のいずれか一項に記載の複合体。
(24)項目1~23のいずれか一項に記載の複合体であって、以下
(24A)前記二本鎖構造は各鎖の端部が互いに結合し一本鎖核酸の形態である、項目1~24のいずれか一項に記載の複合体。
(24B)直鎖状一本鎖RNAまたはその類縁体から構成される、項目1~24または24Aのいずれか一項に記載の複合体。
(24C)前記複合体は、前記二本鎖構造の片端の2つの鎖に、miRNA結合配列を含む2つの鎖の末端が、それぞれ1~5塩基のリンカーを介して1本ずつ結合しており、二本鎖または四本鎖から選択される第2の多重鎖構造を含み、該二本鎖構造と該第2の多重鎖構造とに挟まれるように、該miRNA結合配列を含む2つの鎖のそれぞれの他端が、該第2の多重鎖構造の片端の2つの鎖に、それぞれ1~5塩基のリンカーを介して結合している、項目1~24、24Aまたは24Bのいずれか一項に記載の複合体。
miRNA阻害複合体であって、該miRNA結合配列を含む2つの鎖は、それぞれの鎖がmiRNA結合配列を含み、miRNA結合配列を含む鎖が2つあるものである
(24D)前記miRNA結合配列を含む2つの鎖は、それぞれの鎖がmiRNA結合配列を含み、miRNA結合配列を含む鎖が2つある、項目1~24、24A、24Bまたは24Cのいずれか一項に記載の複合体。
(25)項目1~24、24A、24B、24Cまたは24Dのいずれか一項に記載の複合体を構成するRNAまたはその類縁体。
(26)項目1~24、24A、24B、24Cまたは24Dのいずれか一項に記載の複合体または項目25に記載のRNAまたはその類縁体を製造する方法であって、
A)化学合成により、リボ核酸およびBNAを用いて、目的とするRNAまたはその類縁体の一本鎖の保護体およびその相補体の保護体を合成する工程;
B)生成した該一本鎖の保護体およびその相補体をそれぞれ脱保護する工程;ならびに
必要に応じてC)脱保護した該一本鎖のそれぞれを二本鎖形成条件に配置して二本鎖を形成する工程
を包含する方法。
(27)項目1~24、24A、24B、24Cまたは24Dのいずれか一項に記載の複合体を含む医薬。
(27A)医薬として使用するための、項目1~24、24A、24B、24Cまたは24Dのいずれか一項に記載の複合体。
(27B)項目1~24、24A、24B、24Cまたは24Dのいずれか一項に記載の複合体をそれを必要とする被験者に投与する工程を包含する、疾患または障害の治療または予防の方法。
本発明は、miRNAを効率的かつ特異的に阻害することができるmiRNA阻害複合体の改良型に関する。本発明のmiRNA阻害複合体は、少なくとも1つの二本鎖構造およびmiRNA結合配列(MBS)を含み、miRNA結合配列の2つの鎖が、該二本鎖構造の少なくとも片端の2つの鎖に(通常、それぞれ一本ずつ)結合しており、そのうえで、miRNA阻害複合体は少なくとも1つの架橋核酸(BNA)を含むことを特徴とするものである。本発明の阻害複合体は「S-TuD」と称することもある。なお本発明においては、この二本鎖構造を「第一の」二本鎖構造と呼ぶことで、本発明の複合体に含まれ得るさらなる二本鎖構造と区別できるようにすることがある。本発明の複合体は、一本鎖(すなわち共有結合で結合した1分子)であってもなくてもよく、例えば一本鎖、二本鎖、またはそれ以上の複数の鎖で構成されていてよい。例えば二本鎖構造の片端の2つの鎖に、MBSを含むRNA鎖が、それぞれ一本ずつ結合した、二本鎖RNAからなる複合体は、複合体中に少なくとも1つの架橋核酸(BNA、例えば、BNANC(NMe))を含む限り、本発明に含まれる。また、例えば二本鎖構造の片端の2つの鎖に、少なくとも1つのMBSを含む一本のRNA鎖が結合していてもよい。この場合、MBSを含むRNA鎖により、二本鎖構造の片端の2つの鎖はつながれることになる。二本鎖構造の2つの鎖をつなぐRNAには、MBSが少なくとも1つ含まれているが、例えば2つ、3つ、またはそれ以上含まれていてもよい。二本鎖構造は、ステムループまたはヘアピンを含む。すなわち、二本鎖構造は、ステムループまたはヘアピンに含まれる二本鎖構造であってもよい。
本発明の特徴の一つに、特定の修飾核酸として安定化型核酸、すなわち、二本鎖形成が促進される修飾核酸が含まれることが特徴であり、例えば広義の架橋核酸(BNA)を含めている点がある。
れる少なくとも1つ原子を介して架橋されたBNAであり得る。
架橋鎖に分岐を持つBNAは、これに限定されるものではないが、たとえばBNA(cEt)
(2)また、BNANC(NMe)修飾DNAオリゴヌクレオチドは二本鎖DNA鎖に対する三重鎖形成能にも卓越している。
<1>ヌクレオシド類縁体の合成
((BNA-1)及び(BNA-2))
一般式(BNA-1)及び(BNA-2)で表される化合物は、実施例に記載の方法および本分野の従来技術に基づいて合成できる。反応条件、保護基導入試薬、反応試薬は、具体的には実施例に記載の方法を参考にすることができるが、これに限定されず、本分野の技術常識に基づき使用可能な反応条件、試薬を適宜採用することができる。例えば、特開2000-297097号公報、特開平10-304889号公報に記載の方法を参考にすることができる。また、一般式(BNA-1)及び(BNA-2)におけるBaseとして種々の天然、非天然の核酸塩基およびその他の芳香族複素環や芳香族炭化水素環を有する場合についても、特開平10-304889号公報に記載の方法を参考にして、本発明化合物の原料を合成することができる。
化合物A-1
(2)化合物A-3の合成
(たとえば窒素気流下、)化合物A-2(たとえば146mg,0.23mmol)の溶液(たとえばピリジン溶液(1.5ml))に適切な温度(たとえば氷冷下)、PG5X(式中、PG5は、本明細書に記載の保護基であり、Xは、Cl、Br、Iであり、たとえば塩化メチルスルホニル(45.1ml,0.59mmol)である)を加え、適切な温度(たとえば室温)で適切な時間(たとえば1時間)撹拌する。(たとえば反応溶液に水を加えて)反応をクエンチし、適切な有機溶媒(たとえば酢酸エチル)で抽出し、有機層を(たとえば飽和重曹水、飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)にて乾燥する。溶媒を減圧留去し、化合物A-3を得る。化合物A-3は精製せずに次の反応に用いることもできる。
(3)化合物A-4の合成
化合物A-3(たとえば170mg)の溶液(たとえば水-エタノール溶液(1:2,6ml))に、適切な温度(たとえば室温)で適切な試薬(たとえば1M水酸化ナトリウム水溶液(0.70ml,0.70mmol))を加え、適切な時間(たとえば1時間)撹拌することにより、2’位に(CR1R1’)mzOHを導入する(R1およびR1’は、本明細書に記載の置換基である)。(たとえば10%塩酸水溶液で)中和後、適切な有機溶媒(たとえば酢酸エチル)で抽出する。有機層を(たとえば水、飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=15:1)により)精製し、化合物A-4を得る(たとえば139mg,95%(2段階),白色固体)。
(4)化合物A-5の合成
(たとえば窒素気流下、)化合物A-4(たとえば0.80g,1.28mmol)の溶液(たとえばエタノール溶液(10ml))に、適切な試薬(たとえば20%水酸化パラジウム-炭素粉末(0.60g)、シクロヘキセン(5.2ml,51mmol))を加え、適切な時間(たとえば5時間)、適切な温度条件(たとえば加熱還流)で撹拌することにより、PG2およびPG3を除去する。PG2を除去する工程とPG3を除去する工程は、同一の工程であっても、別々の工程であってもよい。反応溶液を濾過後、溶媒を減圧留去する。得られた粗生成物A-5は、精製せずに次の反応に用いることができる。
(5)化合物A-6の合成
(たとえば窒素気流下、)化合物A-5(たとえば0.46g)の溶液(たとえばN,N-ジメチルホルムアミド溶液(10ml))に、PG6X(式中、PG6は、本明細書に記載の保護基であり、Xは、Cl、Br、Iであり、たとえば1,3-ジクロロ-1,1,3,3-テトライソプロピルジシロキサン(0.45ml,1.41mmol)である)、塩基(たとえばイミダゾール(0.38g,5.63mmol))を加え、適切な温度(たとえば室温)で適切な時間(たとえば5時間)撹拌することによりPG6を導入する。反応液を適切な有機溶媒(たとえばエーテル)で抽出し、有機層を(たとえば水、飽和食塩水で)洗浄した後、適切な乾燥剤(たとえば硫酸マグネシウム)で乾燥する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(n-ヘキサン:酢酸エチル=2:1→1:1)により)精製し、化合物A-6を得る(たとえば0.60g,68%(2段階),白色固体)。
(6)化合物A-7の合成
(たとえば窒素気流下、)化合物A-6(たとえば200mg,0.29mmol)の溶液(たとえばピリジン溶液(3ml))に適切な温度(たとえば氷冷下)、PG5X(式中、PG5は、本明細書に記載の保護基であり、Xは、Cl、Br、Iであり、たとえば無水トリフルオロメタンスルホン酸(0.15ml,0.88mmol))、塩基(たとえば4-(ジメチルアミノ)ピリジン(7mg,0.06mmol))を加え、適切な温度(たとえば室温)で適切な時間(たとえば7.5時間)撹拌する。(たとえば反応溶液に水を加えて)反応をクエンチし、適切な有機溶媒(たとえばジクロロメタン)で抽出する。有機層を(たとえば飽和重曹水、飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥する。溶媒を減圧留去し、化合物A-7を得る。得られるA-7は精製せず、次の反応に用いることができる。
(7)化合物A-8の合成
化合物A-7の2’位のヒドロキシ基にアミノ基を導入した化合物A-8を合成する。その合成法は、これに限定されるものではないが、たとえば以下のようなものである。(たとえば窒素気流下、)化合物A-7(たとえば0.29g)の溶液(たとえばアセトニトリル溶液(3ml))に、適切な温度(たとえば室温)で適切な試薬(たとえばN-ヒドロキシフタルイミド(67mg,0.41mmol)、1,8-ジアザビシクロ[5.4.0]-7-ウンデセン(61(1,0.41mmol))を加え、適切な温度(たとえば室温)で適切な時間(たとえば12時間)撹拌する。反応溶液を適切な有機溶媒(たとえばジクロロメタン)で抽出し、有機層を(たとえば水、飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(クロロホルム)により)精製し、化合物A-7’を得る。得られた化合物A-7’(1.16g,1.40mmol)の溶液(たとえばエタノール溶液(35ml))に、適切な試薬(たとえばヒドラジン-水和物(0.12ml,2.38mmol))を加え、適切な温度(たとえば室温)で適切な時間(たとえば10分間)撹拌する。反応溶液の溶媒を留去後、濾過し、濾液を適切な有機溶媒(たとえば酢酸エチル)で抽出する。有機層を(たとえば水、飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥し、溶媒を減圧留去し、得られたA-8は精製せず、次の反応に用いることができる。
(8)化合物A-9の合成
(たとえば窒素気流下)化合物A-8(0.93g)の溶液(たとえば塩化メチレン溶液(15ml))に適切な温度(たとえば氷冷下)、適切な試薬(たとえば飽和重曹水(4.0ml,4.2mmol))、PG7X(式中、PG7は、本明細書に記載の保護基であり、Xは、Cl、Br、Iであり、たとえばクロロギ酸ベンジル(0.30ml,2.1mmol)である)を加え、適切な時間(たとえば1時間)撹拌する。反応を(たとえば飽和重曹水を加えて)クエンチし、適切な有機溶媒(たとえば酢酸エチル)で抽出する。有機層を(たとえば水、飽和食塩水で)洗浄し、適切な乾燥剤(たとえば硫酸マグネシウム)で乾燥する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(n-ヘキサン:酢酸エチル=4:1)により)精製し、化合物A-9を得る(たとえば0.92g,94%(2段階),白色固体)。
(9)化合物A-10の合成
(たとえば窒素気流下、)塩基(たとえば水素化ナトリウム(60% in oil,0.55g,13.7mmol)のテトラヒドロフラン懸濁液(25ml))に適切な温度(たとえば氷冷下)、化合物A-9(たとえば3.81g,4.57mmol)の溶液(たとえばテトラヒドロフラン溶液(15ml))を滴下し、適切な時間(たとえば1時間)撹拌後、適切な温度(たとえば室温)で適切な時間(たとえば5時間)撹拌することによりOPG4を除去するとともに2’位と4’位を架橋する。OPG4を除去する工程と2’位と4’位を架橋する工程は同一の工程であっても、異なる工程であってもよい。(たとえば飽和シュウ酸水溶液で)中和後、適切な有機溶媒(たとえば酢酸エチル)で抽出する。有機層を(たとえば水、飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(クロロホルム→クロロホルム:メタノール=100:1)により)精製し、化合物A-10を得る(たとえば2.87g,95%,白色固体)。
(10)化合物A-11の合成
(たとえば窒素気流下、)化合物A-10(たとえば0.35mg,0.53mmol)の溶液(たとえば塩化メチレン溶液(10ml))に適切な温度(たとえば氷冷下)、適切な試薬(たとえば1M三塩化ホウ素ヘキサン溶液(5.29ml,5.29mmol))を加え、適切な時間(たとえば1時間)撹拌する。(たとえば反応溶液に飽和重曹水を加えることにより)反応をクエンチし、適切な有機溶媒(たとえば酢酸エチル)で抽出し、有機層を(たとえば水、飽和食塩水で)洗浄した後、適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=50:1)により)精製し、化合物A-11を得る(たとえば0.27g,96%,白色固体)。
(11)化合物A-12の合成
化合物A-11(0.19g,0.36mmol)の溶液(たとえば1M p-トルエンスルホン酸ピリジニウム-メタノール溶液(3.6ml))に、適切な温度(たとえば室温)にて適切な試薬(たとえば20%ホルムアルデヒド水溶液(0.06ml,0.40mmol))を加え、適切な時間(たとえば10分間)撹拌する。さらに、適切な温度(たとえば氷冷下)において適切な試薬(たとえばシアン化水素化ホウ素ナトリウム(45mg,0.72mmol))を加えて置換基R3(R3は、本明細書に記載の置換基である)によりアミノ基を置換する。適切な時間(たとえば1時間)撹拌する。反応溶液を適切な有機溶媒(たとえば酢酸エチル)で抽出し、(たとえば水、飽和重曹水、飽和食塩水)で洗浄し、有機層を適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(n-ヘキサン:酢酸エチル=2:1)にて)精製し、化合物A-12を得る(たとえば0.19g,100%,白色固体)。
(12)化合物A-13の合成
化合物A-12(46mg,0.085mmol)の溶液(たとえばテトラヒドロフラン溶液(2ml))に適切な試薬(たとえばフッ化テトラ-n-ブチルアンモニウム(1M テトラヒドロフラン中,0.17ml,0.17mmol))を加え、適切な温度(たとえば室温)で適切な時間(たとえば5分間)撹拌する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(酢酸エチル:メタノール=15:1により)精製し、化合物A-13を得る(たとえば25mg,100%,白色固体)。
(13)化合物A-14の合成
化合物A-13(たとえば0.16g,0.54mmol)の溶液(たとえばピリジン溶液(10ml))に適切な試薬(たとえば塩化4,4’-ジメトキシトリチル(たとえば0.22g,0.64mmol))を加え、適切な温度(たとえば室温)で適切な時間(たとえば12時間)撹拌する。反応液に(たとえば飽和重曹水を加え、適切な有機溶媒(たとえば酢酸エチル)で抽出し、有機層を(たとえば水、飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥する。溶媒を減圧留去し、得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(1%トリエチルアミン含有n-ヘキサン:酢酸エチル=1:2→酢酸エチル:メタノール=30:1)にて)精製し、化合物A-14を得る(たとえば0.30g,93%,白色固体)。
(14)化合物A-15の合成
化合物A-14(たとえば0.17g,0.28mmol)及び適切な試薬(たとえば4,5-ジシアノイミダゾール(40mg,0.34mmol))の溶液(たとえばアセトニトリル溶液(6ml))に、適切な試薬(たとえば2-シアノエチル-N,N,N’,N’-テトライソプロピルホスホロアミダイト(0.13ml,0.42mmol))を加え、適切な温度(たとえば室温)で適切な時間(たとえば4時間)撹拌することにより3’位のヒドロキシ基をP(O)(OPG9)(OPG10)(PG9およびPG10は、それぞれ独立して本明細書に記載の保護基である)により修飾する。(たとえば反応液に飽和重曹水を加えて)クエンチし、適切な有機溶媒(たとえば酢酸エチル)で抽出する。有機層を(たとえば飽和重曹水、水、飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)で乾燥し、溶媒を減圧留去する。得られた粗生成物を(たとえばシリカゲルカラムクロマトグラフィー(1%トリエチルアミン含有n-ヘキサン:酢酸エチル=1:1)、ついで再沈澱(酢酸エチル-ヘキサン)により)精製し、化合物A-15を得る(たとえば0.20g,88%,白色固体)。
一般式BNA-3で表される化合物は、実施例に記載の方法および本分野の従来技術に基づいて合成できる。反応条件、保護基導入試薬、反応試薬は、具体的には実施例に記載の方法を参考にすることができるが、これに限定されず、本分野の技術常識に基づき使用可能な反応条件、試薬を適宜採用することができる。例えば、J.Org.Chem.2010,75,1569-1581に記載の方法を参考にすることができる。また、一般式(BNA-3)におけるBaseとして種々の天然、非天然の核酸塩基およびその他の芳香族複素環や芳香族炭化水素環を有する場合についても、J.Org.Chem.2010,75,1569-1581に記載の方法を参考にして、本発明化合物の原料を合成することができる。
BNA-3の一般合成例
化合物B-1
(たとえば窒素気流下、)化合物B-2の溶液に適切な温度(たとえば室温)、適切な試薬(たとえば2,3-ジクロロ-5,6-ジシアノ-p-ベンゾキノン(DDQ)である)を加え、適切な温度(たとえば室温)で適切な時間(たとえば12時間)撹拌する。(たとえば反応溶液に水を加えて)反応をクエンチし、適切な有機溶媒(たとえば酢酸エチル)で抽出し、有機層を(たとえば飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)にて乾燥する。溶媒を減圧留去し、化合物B-3を得る。
(たとえば窒素気流下、)化合物B-3の溶液に適切な温度(たとえば氷冷下)、適切な試薬(たとえばトリエチルアミン三フッ化水素酸塩)を加え、適切な温度(たとえば室温)で適切な時間(たとえば12時間)撹拌する。(たとえば反応溶液に水を加えて)反応をクエンチし、適切な有機溶媒(たとえば酢酸エチル)で抽出し、有機層を(たとえば飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)にて乾燥する。溶媒を減圧留去し、化合物B-4を得る。
(たとえば窒素気流下、)化合物B-4の溶液に適切な温度(たとえば室温)、PG5X(式中、PG5は、本明細書に記載の保護基であり、Xは、Cl、Br、Iであり、たとえば塩化ジメトキシトリチルである)を加え、適切な温度(たとえば室温)で適切な時間(たとえば12時間)撹拌する。(たとえば反応溶液に水を加えて)反応をクエンチし、適切な有機溶媒(たとえば酢酸エチル)で抽出し、有機層を(たとえば飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)にて乾燥する。溶媒を減圧留去し、化合物B-5を得る。
(たとえば窒素気流下、)化合物B-5の溶液に適切な温度(たとえば室温)、適切な試薬(たとえば2-シアノエチル-N,N,N’,N’-テトライソプロピルホスホロアミダイト)を加え、適切な温度(たとえば室温)で適切な時間(たとえば4時間)撹拌することにより3’位のヒドロキシ基をP(O)(OPG6)(OPG7)(PG6およびPG7は、それぞれ独立して本明細書に記載の保護基である)により修飾する。(たとえば反応溶液に水を加えて)反応をクエンチし、適切な有機溶媒(たとえば酢酸エチル)で抽出し、有機層を(たとえば飽和食塩水で)洗浄後、適切な乾燥剤(たとえば無水硫酸ナトリウム)にて乾燥する。溶媒を減圧留去し、化合物B-6を得る。
本発明のヌクレオシド類縁体を含むオリゴヌクレオチド類縁体は、公知のDNAシンセサイザーを用いて種々合成することができる。次いで、得られるオリゴヌクレオチド類縁体を、逆相カラムを用いて精製し、生成物の純度を逆相HPLCやMALDI-TOF-MSで分析することにより、精製オリゴヌクレオチド類縁体の生成を確認できる。本発明のヌクレオシド類縁体は、オリゴヌクレオチド類縁体の中に1個以上存在させることができる。また、オリゴヌクレオチド類縁体の2カ所以上の位置に、1又は2以上の天然ヌクレオチドを介して隔離された状態で存在させてもよい。本発明によれば、本発明のヌクレオシド類縁体を必要な位置に必要な数(長さ)で導入したオリゴヌクレオチド類縁体を合成することができる。オリゴヌクレオチド類縁体全体の長さとしてヌクレオチド単位が2~50、好ましくは8~30個である。
本発明のオリゴヌクレオチド類縁体は、ヌクレアーゼに対して分解されにくく、生体への投与後、長く生体内に存在することができる。そして、例えば、センスRNAと二重鎖を形成して病因となる生体内成分(タンパク質)のmRNAへの転写を阻害する。また、感染したウイルスの増殖を阻害すると考えられる。
本発明で使用されるS-TuDを構成するオリゴヌクレオチドは、合成機(たとえばnS-8II 合成機もしくは、AKTA oligopilot合成機)で合成する。細孔ガラス質固相担体(たとえば2’-O-メチル-RNA CPG Link Technologies社製)と、標準的な保護基を有する2’-O-メチル-RNAホスホロアミダイト、(たとえば、これに限定するものではないが、5’-O-ジメトキシトリチルN6-ベンゾイルアデノシン-2’-O-メチル-3’-O-N,N’-ジイソプロピルホスホロアミダイト、5’-O-ジメトキシトリチル-N4-アセチルシチジン-2’-O-メチル-3’-O-N,N’-ジイソプロピルホスホロアミダイト、5’-O-ジメトキシトリチル-N2-イソブチリルグアノシン-2’-O-メチル-3’-O-N,N’-ジイソプロピルホスホロアミダイト、および5’-O-ジメトキシトリチルウリジン-2’-O-メチル-3’-O-N,N’-ジイソプロピルホスホロアミダイト(以上シグマアルドリッチ社製)、並びに、2’,4’-BNANC(2’-O,4’-C-アミノメチレン架橋核酸)チミジンホスホロアミダイト、すなわち2’-O,4’-C-アミノメチレン-5’-O-ジメトキシトリチル-チミジン-N,N’-ジイソプロピルホスホロアミダイト、2’,4’-BNANCアデノシンホスホロアミダイト、すなわち2’-O,4’-C-アミノメチレン-5’-O-ジメトキシトリチル-N6-ベンゾイルアデノシン-N,N’-ジイソプロピルホスホロアミダイト(以上BNA社製)、並びに、LNA(Locked nucleic acid)(2’-O,4’-C-メチレンリボ核酸)チミジンホスホロアミダイト、すなわち2’-O,4’-C-メチレン-5’-O-ジメトキシトリチルチミジン-N,N’-ジイソプロピルホスホロアミダイト(エキシコン社製)が挙げられる)をオリゴヌクレオチド合成に使用する。ホスホロアミダイトは全て、適切な溶媒(たとえばアセトニトリル(CH3CN))中、適切な濃度(たとえば0.1M)で使用する。2’-O-メチルRNA、BNA及びLNAについては適切な連結/再利用時間(たとえば15分)を使用する。活性剤は、たとえば、これに限定されるものではないが、5-ベンジルメルカプト-テトラゾール(0.25M、和光純薬社製)であり、PO-酸化については、たとえば、これに限定されるものではないが、ヨウ素/水/ピリジンを使用する。PS-チオエート化については、たとえば、これに限定されるものではないが、市販のオリゴヌクレオチド自動合成機用硫化試薬(すなわちEIDTH、DDTT、PADS、Beucage試薬など)を適切な試薬(たとえばピリジン)とともに使用する。
合成が完了した後、合成担体を適切な容器(たとえばガラスボトル)に移す。オリゴヌクレオチドを、担体1gに対して15mLの、40%メチルアミン水溶液と33%メチルアミンエタノール溶液の等量混合物を用いて、適切な温度(たとえば45℃)で適切な時間(たとえば13時間)、塩基とリン酸基を脱保護して担体から切断する。塩基を脱保護する工程とリン酸基を脱保護する工程は、同一であっても、異なっていてもよい。その後、エタノールアンモニア混合物を濾過して、適切な容器(たとえば新しい250mLのボトル)に入れる。担体を(たとえば2×40mLのエタノール/水(1:1 v/v)で)洗浄する。その後、(たとえばロータリーエバポレーター(roto-vap)を用いて)溶媒を留去し乾固する。
オリゴヌクレオチドを、HPLC(たとえばSource 15 RPCゲルカラムでの逆相イオンペアHPLC)で精製する。緩衝液は、たとえば、これに限定されるものではないが、5% CH3CN、0.1M トリエチルアミン酢酸緩衝液(pH7.0)(緩衝液A)と90% CH3CN、0.1M トリエチルアミン酢酸緩衝液(pH7.0)(緩衝液B)である。5’末端に保護基(たとえばジメトキシトリチル基)が保持された状態で全長のオリゴヌクレオチドを含む画分をプールし次の精製に供する。その後オリゴヌクレオチドプールを、HPLC(たとえばSource 30Qの陰イオンペアHPLC)で精製する。溶液及び緩衝液は、たとえばこれに限定されるものではないが、0.6%のトリフルオロ酢酸(溶液A)、20mMリン酸ナトリウム緩衝液(pH7.5)(緩衝液C)と20mMリン酸ナトリウム緩衝液中の2M塩化ナトリウム(緩衝液D)である。5’末端の保護基を脱離させた後、完全長のオリゴヌクレオチドを含む画分をプールし、脱塩後凍結乾燥する。化合物を、最終的に、たとえばMALDI-TOF/MSと変性ポリアクリルアミドゲルで分析する。
精製の完了した1本鎖オリゴヌクレオチドを適切な溶媒(たとえば蒸留水)にて溶解後、(たとえば紫外分光光度計を用い吸光度測定することにより)オリゴヌクレオチド濃度を決定する。決定された濃度を用い相補鎖をそれぞれ等モル濃度になるように混合し適切な温度(たとえば95℃)で適切な時間(たとえば10分)加熱後徐冷し2本鎖形成させる。2本鎖形成はたとえば非変性ゲル電気泳動にて確認する。
本発明のmiRNA阻害複合体は直鎖状の一本鎖核酸により構成されるように設計することができる(図31)。本発明は特に、MBSの全てがある二本鎖構造(図31のステムI)の片側(図31においては右側)に集中しており、該二本鎖構造の各鎖は、その側で閉じた構造となっており(すなわちMBSを含む配列によりつながっており)、該二本鎖構造の反対側に一本鎖RNAの両端があるような複合体に関する(図31)。MBSを含む配列中には、さらなる二本鎖構造(図31のステムIIやIIIなど)を含んでもよい。一本鎖RNAの長さは適宜決めてよいが、例えば500塩基内、好ましくは450塩基以内、420塩基以内、400塩基以内、380塩基以内、360塩基以内、340塩基以内、320塩基以内、300塩基以内、280塩基以内、260塩基以内、240塩基以内、220塩基以内、200塩基以内、180塩基以内、160塩基以内、140塩基以内、120塩基以内、100塩基以内、または80塩基以内である。例えば2つの二本鎖構造と2つのMBSを持つ複合体を形成する一本鎖RNAの長さは、例えば60~300塩基、好ましくは70~250塩基、80~200塩基、90~180塩基、または100~150塩基である。第一の二本鎖構造(一本鎖RNAの両端に近い二本鎖構造)は、例えば15~30bp、好ましくは16~28bp、好ましくは17~25bp、好ましくは17~24bp、例えば17bp、18bp、19bp、20bp、21bp、22bp、23bp、または24bpとすることができ、第二の二本鎖構造(MBSを含む配列中に含まれるさらなる二本鎖構造)は、全体をコンパクトにするために、第一の二本鎖構造の長さよりも短くしてもよく、例えば4bp~20bpであり、例えば5bp~15bp、5bp~12bp、5bp~10bp、6bp~9bp、または7bp~8bpとしてよい。
以下に本発明の好ましい実施形態を説明する。以下に提供される実施形態は、本発明のよりよい理解のために提供されるものであり、本発明の範囲は以下の記載に限定されるべきでないことが理解される。従って、当業者は、本明細書中の記載を参酌して、本発明の範囲内で適宜改変を行うことができることは明らかである。また、本発明の以下の実施形態は単独でも使用されあるいはそれらを組み合わせて使用することができることが理解される。
別の局面において、本発明は、本発明の複合体を含む医薬を提供する。
さらなる局面において、本発明は、有効量の本発明の複合体またはそれを含む医薬をそれを必要とする被験体に投与する工程を包含する、疾患または障害を治療または予防する方法を提供する。本発明は、限定されないが、例えば、すでに臨床開発が進んでいるHCV治療薬や腎臓の線維化治療剤としての利用等に応用することができる。
(オリゴヌクレオチドの合成)
オリゴヌクレオチドは、nS-8II合成機もしくはAKTAoligopilot合成機で合成した。市販の細孔ガラス質固相担体(2’-O-メチル-RNA CPG Link Technologies社製)と、標準的な保護基を有する2’-O-メチル-RNAホスホロアミダイト、すなわち、5’-O-ジメトキシトリチルN6-ベンゾイルアデノシン-2'-O-メチル-3’-O-N,N’-ジイソプロピルホスホロアミダイト、5’-O-ジメトキシトリチル-N4-アセチルシチジン-2'-O-メチル-3’-O-N,N’-ジイソプロピルホスホロアミダイト、5’-O-ジメトキシトリチル-N2-イソブチリルグアノシン-2'-O-メチル-3’-O-N,N’-ジイソプロピルホスホロアミダイト、および5’-O-ジメトキシトリチルウリジン-2'-O-メチル-3’-O-N,N’-ジイソプロピルホスホロアミダイト(以上シグマアルドリッチ社製)、並びに、2’,4’-BNANC(2’-O,4’-C-アミノメチレン架橋核酸)チミジンホスホロアミダイト、すなわち2’-O,4’-C-アミノメチレン-5’-O-ジメトキシトリチル-チミジン-N,N'-ジイソプロピルホスホロアミダイト、2’,4’-BNANCアデノシンホスホロアミダイト、すなわち2’-O,4’-C-アミノメチレン-5’-O-ジメトキシトリチル-N6-ベンゾイルアデノシン-N,N'-ジイソプロピルホスホロアミダイト(以上BNA社製)、並びに、LNA(Locked nucleic acid)(2’-O,4’-C-メチレンリボ核酸)チミジンホスホロアミダイト、すなわち2’-O,4’-C-メチレン-5’-O-ジメトキシトリチルチミジン-N,N'-ジイソプロピルホスホロアミダイト(エキシコン社製)をオリゴヌクレオチド合成に使用した。ホスホロアミダイトは全て、アセトニトリル(CH3CN)中、0.1Mの濃度で使用した。2’-O-メチルRNA、BNA及びLNAについては15分の連結/再利用時間を使用した。活性剤は、5-ベンジルメルカプト-テトラゾール(0.25M、和光純薬社製)であり、PO-酸化については、ヨウ素/水/ピリジンを使用した。PS-ホスホロチオエート化については、市販のオリゴヌクレオチド自動合成機用硫化試薬(すなわちEIDTH、DDTT、PADS、Beucage試薬など)をピリジンとともに使用した。
合成が完了した後、合成担体をガラスボトルに移した。オリゴヌクレオチドを、担体1gに対して15mLの、40%メチルアミン水溶液と33%メチルアミンエタノール溶液の等量混合物を用いて、45℃で13時間、塩基とリン酸基を同時に脱保護しながら担体から切断した。その後、エタノールアンモニア混合物を濾過して、新しい250mLのボトルに入れた。担体を2×40mLのエタノール/水(1:1v/v)で洗浄した。その後、ロータリーエバポレーター(roto-vap)で溶媒留去し乾固した。
オリゴヌクレオチドを、Source 15 RPCゲルカラムでの逆相イオンペアHPLCで精製した。緩衝液は、5% CH3CN、0.1Mトリエチルアミン酢酸緩衝液(pH7.0)(緩衝液A)と90% CH3CN、0.1Mトリエチルアミン酢酸緩衝液(pH7.0)(緩衝液B)であった。5’末端にジメトキシトリチル基が保持された状態で全長のオリゴヌクレオチドを含む画分をプールし次の精製に供した。その後オリゴヌクレオチドプールを、Source30Qの陰イオンペアHPLCで精製した。溶液及び緩衝液は、0.6%のトリフルオロ酢酸(溶液A)、20mMリン酸ナトリウム緩衝液(pH7.5)(緩衝液C)と20mMリン酸ナトリウム緩衝液中の2M塩化ナトリウム(緩衝液D)であった。溶液Aを用い、ジメトキシトリチル基を脱離させた後、完全長のオリゴヌクレオチドを含む画分をプールし、脱塩後凍結乾燥した。化合物は、最終的に、MALDI-TOF/MSと変性ポリアクリルアミドゲルで分析した。
精製の完了した1本鎖オリゴヌクレオチドを蒸留水にて溶解後、紫外吸光光度分析計を用い吸光度測定しオリゴヌクレオチド濃度を決定した。決定された濃度を用い相補鎖をそれぞれ等モル濃度になるように混合し、95℃で10分加熱後徐冷し2本鎖形成させた。2本鎖形成は非変性ゲル電気泳動にて確認した。
(HeLaS3-miR199a細胞の作製および培養)
HeLaS3細胞は10%ウシ胎児血清(FBS)を含むDMEM中、37℃で培養した。HeLaS3細胞を6ウェルプレートに1ウェルあたり1x105細胞(1x105 cells per well)でまき、24時間後にpLSP-miR199aウイルスベクター(<1x104 TU)を、8μg/mlのポリブレンの存在下で導入し、トランスダクションの24時間後からピューロマイシン(Puromycin)(1ug/ml)で選択した。1週間の選択の後、培地からピューロマイシン(Puromycin)を除去し、miR-199aレポーターを保持するHeLaS3細胞としてHeLaS3-miR199a細胞を得た。
HeLaS3-miR199a細胞およびHCT-116細胞を、10%ウシ胎児血清(foetal bovine serum)(FBS)を含むDMEM中、それぞれ1ウェルあたり1x105細胞(1.0x105 cells per well)で導入の前日に24ウェルプレートにまき、Lipofectamine 2000 (LifeTechnologies)および100ngのレポータープラスミド(psiCHECKTM-2,psiCHECK2-T199a-3px3,psiCHECK2-T200c-3pまたはpsiCHECK2-T21-5p)(図16および図17を参照)および各種S-TuDをトリプリケートでトランスフェクトした。全てのアッセイはトランスフェクションの48時間後にdual luciferase assay(Promega)によりGLOMAXTM(Promega)で実施した。
本発明者らが開発したmiRNA阻害剤(合成Tough Decoy,S-TuD)は低濃度でmiRNAの活性を阻害する核酸として注目されているが、その構造の特性上2本鎖化した後の物性が安定しない。そこで、本実施例では、S-TuDの安定的な大量生産及び物性試験法の確立を容易にするために、2本鎖を強固にする方法として2本鎖領域をハイブリダイゼーション能力が向上する修飾核酸に部分置換したものを使用し、miRNA阻害活性を従来型のS-TuDと比較した(図1A)。
STEM領域の一部塩基を2本鎖形成能が上昇するタイプのヌクレオチド種(BNANC(NMe))に変更し、物性評価を実施した。結果を図38に示す。その結果、図1BのピークAが減少し、2本鎖の逆相HPLC純度分析精度が向上した。
miR199a_3p及び5pを内在性に僅かにしか発現しないHeLaS3細胞(Landgraf, P. et al. (2007) Cell, 129, 1401-1414)を10%ウシ胎児血清(foetal bovine serum)(FBS)を含むDMEM中、37℃で培養した。HeLaS3細胞を6ウェルプレートに1ウェルあたり1x105細胞(1x105 cells per well)でまき、24時間後にpLSP-miR199aウイルスベクター(<1x104 TU)を、8μg/mlのポリブレンの存在下で導入し、トランスダクションの24時間後からピューロマイシン(Puromycin)(1ug/ml)で選択した。1週間の選択の後、培地からピューロマイシン(Puromycin)を除去し、miR-199aレポーターを保持するHeLaS3細胞としてHeLaS3-miR199a細胞を得た。
psiCHECK2-miRT(プロメガ社、XhoI-NotIサイトに、例えば、miR-199a-3pのような標的miRNAと相補な配列を挿入して作成;全体構造は図3に示す。)、図2に示された、合成S-TuD修飾体を用いて細胞(HeLaS3-miR199a)をトランスフェクションした。
本実施例ではMBS領域等種々の位置においてBNANC(NMe)に置換した場合の影響を確認した。実施例1と同じレポーターアッセイ系を用いた。使用した配列は、図10、12および13に示す。
本実施例では、まず、挿入部位の最適化のために、種々の構造の物を用いてBNANC(NMe)に置換した場合の影響を確認した、使用したS-TuDの構造は図6~7に示す。オリジナルのS-TuD199a-3p、(16)S-TuD-miR-199a-3p-1_18-pf-L18B6-2、(22)S-TuD-miR-199a-3p-1_18-pf-L18B6-2-MBSB1(seed領域の相補配列をBNANC(NMe)化)、(23)S-TuD-miR-199a-3p-1_18-pf-L18B6-2-MBSB2(非seed領域の相補配列をBNANC(NMe)化)、(24)S-TuD-miR-199a-3p-1_18-pf-L18B6-3-MBSB2 (非seed領域の相補配列をBNANC(NMe)化)を示す。修飾核酸(BNANC(NMe))、(17)S-TuD199a-3p-1_18-pf-S10-BT6-MBSB1(seed領域の相補配列をBNANC(NMe)化)、(18)S-TuD199a-3p-1_18-pf-S10-BT6-MBSB2(非seed領域の相補配列をBNANC(NMe)化)、(23)-(1)S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS1(非seed領域の相補配列をBNANC(NMe)化及びMBS領域をホスホロチオエート化)、(23)-(2) S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS2(非seed領域の相補配列をBNANC(NMe)化及びSTEM領域をホスホロチオエート化)、(23)-(3)S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS3(非seed領域の相補配列をBNANC(NMe)化及び全配列ホスホロチオエート化)が使用された。
実施例1と同じレポーターアッセイを用いた。
本実施例で得られた構造体について、MBS領域の一部BNANC(NMe)に置換した結果を図8-1および図8-2に示す。図8-1および図8-2に示されるように、オリジナルのS-TuDに比較し最大10倍程度の阻害活性向上が見られる構造体を得ることができた。MBS領域の非シード領域にBNAを一部挿入することが重要であった。
次に本実施例では、実施例1~2の結果を受け、STEM領域短鎖化+MBS領域へのBNA挿入効果確認を行った。
本実施例において使用したS-TuDの構造を図10に示す。S-TuD199a-3pのオリジナル配列、(16)S-TuD-miR-199a-3p-1_18-pf-L18B6-2、(1)’S-TuD199a-3p-1_18-pf-S10、(6)’S-TuD199a-3p-1_18-pf-S10-BT6、(17)S-TuD199a-3p-1_18-pf-S10-BT6-MBSB1(seed領域の相補配列をBNANC(NMe)化)、(18)S-TuD199a-3p-1_18-pf-S10-BT6-MBSB2(非seed領域の相補配列をBNANC(NMe)化)を使用した。
実験方法は、実施例1~2に記載されているレポーターアッセイの方法と同様の手法で発現を確認した。
個々のS-TuD 100pMおよび300pMでの結果を図11-1および図11-2に示す。図11-1および図11-2に示されるように、Short typeについてBNA修飾の影響を検討した。オリジナルタイプとLong typeのStem-BNA修飾(16)を比較に加えた。Short type-BNA修飾無(1)’と比べて、stem部分にBNA修飾を入れた(6)’は大きく効果が増強した。さらにSeed相当部位にBNA修飾をいれた(17)は効果を増強しなかった。しかし非seed相当部位にBNA修飾を入れた(18)はさらに効果が増強し、(16)と同等以上になった。Short typeにおいてはMBS内のBNA修飾部位によっては増強効果があることが分かった。
次に、本実施例では、マウス血清を用いて血清中の安定性を確認した。
オリジナルのS-TuDと比較して、血清安定性が向上することを血清安定性試験により確認した。以下にプロトコールを示す。実験は、2μg S-TuD/100% 20μlマウス血清の条件で、37℃中で0h、48h、72h、96h処理した。
使用した修飾S-TuDの構造は、図12~13及び図19に示す。すなわち、オリジナル構造、(16)S-TuD-miR-199a-3p-1_18-pf-L18B6-2、(23)S-TuD-miR-199a-3p-1_18-pf-L18B6-2-MBSB2(非seed領域の相補配列をBNANC(NMe)化)、(23)-(1)S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS1(非seed領域の相補配列をBNANC(NMe)化)、(23)-(2)S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS2(非seed領域の相補配列をBNANC(NMe)化)および(23)-(3)S-TuD-miR-199a-3p-1_18-pf-L18B6-2-PS3(非seed領域の相補配列をBNANC(NMe)化)、(1)’S-TuD199a-3p-1_18-pf-S10、(6)’S-TuD199a-3p-1_18-pf-S10-BT6、(17)S-TuD199a-3p-1_18-pf-S10-BT6-MBSB1(seed領域の相補配列をBNANC(NMe)化)および(18)S-TuD199a-3p-1_18-pf-S10-BT6-MBSB2(非seed領域の相補配列をBNANC(NMe)化)、(41)S-TuD-200c-1_22-pf、(42)S-TuD-200c-1_22-pf-L18B6、(43)S-TuD-200c-1_22-pf-L18B6-MBSB1(seed領域の相補配列をBNANC(NMe)化)、(44)S-TuD-200c-1_22-pf-L18B6-MBSB2(非seed領域の相補配列をBNANC(NMe)化)、(45)S-TuD-200c-1_22-pf-S10-BT6-MBSB2(非seed領域の相補配列をBNANC(NMe)化)である。
結果を図14~図15及び図20に示す。図14~15及び図20で示されるように、MBS領域の一部BNANC(NMe)に置換した結果血清安定性の向上が見られた。
本実施例では、普遍性を確認するために2種類のmiRNAを標的として同種の実験を行った。
実施例1におけるmiR-199aに代えて、miR-200c、miR-21に置換したものを用いて同様にレポーターアッセイ実験を行った。具体的には以下のとおりである。
miR-200cのための構造は、図19に示す。miR-21のための構造は図23に示す。miR-200cには(41)S-TuD-200c-1_22-pf、(42)S-TuD-200c-1_22-pf-L18B6、(43)S-TuD-200c-1_22-pf-L18B6-MBSB1(seed領域の相補配列をBNANC(NMe)化)、(44)S-TuD-200c-1_22-pf-L18B6-MBSB2(非seed領域の相補配列をBNANC(NMe)化)、(45)S-TuD-200c-1_22-pf-S10-BT6-MBSB2(非seed領域の相補配列をBNANC(NMe)化)を使用した。miR-21には、(51)S-TuD-21-1_17-10mut、(52)S-TuD-21-1_17-10mut-L18B6、(53)S-TuD-21-1_17-10mut-L18B6-MBSB1、(54)S-TuD-21-1_17-10mut-S10-BT6、(55)S-TuD-21-1_17-10mut-S10-BT6-MBSB1を使用した。
次に、普遍性の確認を確認した。普遍性は、miR-199a以外にmiR-200c、miR-21についても実施例1と同様の実験を行った。図20には血清耐性を示す電気泳動の結果を示す。miR-200cでの結果をグラフ化したものを図21-1および図21-2(miR-200c)に示す。レポーターアッセイの結果を示す図21-1および図21-2に示されるように、Long type(Stem1=18,Stem2=10)のStemをBNA化した場合(42)、そのMBSの非seed領域の相補配列にさらにBNANC(NMe)修飾を入れても抑制効果は増強しなかった(44)。この42MBSのseed領域の相補配列にさらにBNANC(NMe)修飾を入れると抑制効果は減弱した(43)。Short type(Stem1=10,Stem2=10)のStemをBNANC(NMe)化しそのMBSの非seed領域の相補配列をさらにBNANC(NMe)修飾した場合(45)、そのlong type(44)とほぼ同程度にまで効果が増強された。また、図22に示されるように、Short type(Stem1=10,Stem2=10)のStemをBNANC(NMe)化しそのMBSの非seed領域の相補配列をさらにBNA修飾した場合(45)はBNANC(NMe)修飾の全くないoriginal(41)の2倍弱程度効果が高かった。0.1-10pMの投与では、S-TuDがチューブに非特異的に吸着する可能性も考え、担体としてS-TuD NC2を30pM添加したものも解析したが、添加の効果は見られなかった。
199a、200c、21全てにおいてlong typeかつBNA修飾をStem部分とMBSの非seed相当部位の両方にいれたもの(Aと略す)が最も効果が高かった。Short typeのStem,MBS-BNA修飾型はAよりは効果が下がるが、originalよりは阻害効果が大きく高くなっていた。BNANC(NMe)修飾long typeの増強程度は199a、21では従来型の10倍弱程度活性が高くなっていた。BNANC(NMe)修飾short typeの増強程度は199a、21では従来型の3-8倍程度活性が高くなっていた。200cで増強程度が低いのはmiR-200cの発現量・活性が低いためか、すでにpMレベルで阻害効果が出ているので、差が出にくいのではないかと考えられる。
次に、本実施例では、本発明のS-TuDが臨床応用できるかを確認した。
使用した構造を図27に示す。(51)S-TuD-21-1_17-10mut、(53)S-TuD-21-1_17-10mut-L18B6-MBSB1および(55)S-TuD-21-1_17-10mut-S10-BT6-MBSB1が使用された。
マウス(C57BL/6 6週齢 オス )へ各S-TuDを1mg/kgで眼窩静脈に単回投与して(n=3)、24hr後にサクリファイスして腎臓を採取し、RT-PCR法で(S-TuDと結合していないと考えられるフリーの)miR-21量を定量した。
結果を図28~29に示す。
次に本実施例では、実施例1~7の結果を受け、STEM領域へ2本鎖化形成能が高い修飾塩基置換を行うことがmiRNA阻害の活性を向上させることを確認するため、BNANC(NMe)と同位置に架橋構造が異なるLocked核酸(LNA;2’-O,4’-C-メチレンリボ核酸)置換を行い、活性を比較した。
配列構造は図32に示す。
アッセイ方法としては、実施例1等で使用したmiR199aのルシフェラーゼレポーターアッセイと同じ手法を用いた。
結果を図33-1および図33-2に示す。BNANC(NMe)とLNAは同等の効果があり、構造普遍性を確認した。また10bpのSTEM領域に6カ所のBNANC(NMe)置換を実施しても活性は4ヵ所の置換と同等であった。
次に本実施例では、STEM領域の短鎖化を行い、活性を比較した。
結果を図35-1および図35-2に示す。STEM領域を8bp以下にすると活性が5分の1以下に減少した。ただし6bpでも濃度依存的に活性上昇がみられることから、STEM領域は10bp以上あった方が望ましく、また図32の結果と合わせて考えるとSTEM長10bp以下の場合はBNA置換が望ましいことが確認された。
本実施例では、STEM領域短鎖化と架橋型核酸置換の組み合わせを、オリジナルのS-TuD(STEM I18bp STEM II 10bp)とオリジナルのS-TuDにSTEM I及びIIそれぞれにBNA置換したS-TuDを比較して総合的に評価した。
使用した配列の構造は図36に示す。アッセイ方法としては実施例1等において示したmiR199aのルシフェラーゼレポーターアッセイと同様の手法を用いた。
結果を図37-1および図37-2に示す。S-TuDのmiRNA阻害活性は、オリジナルを1とすると、オリジナルのS-TuDにSTEM I及びIIそれぞれにBNA置換したS-TuDが3倍以上、STEM Iを10bpに短鎖化してBNANC(NMe)置換したS-TuDが約3倍の活性向上となった。このことによりSTEMの2本鎖形成を強固にすることがS-TuDのmiRNA阻害活性に大きな役割を果たすことが示された。
配列番号2:図2Aのオリジナルアンチセンス配列
配列番号3:図2A(1)のセンス配列
配列番号4:図2A(1)のアンチセンス配列
配列番号5:図2A(2)のセンス配列
配列番号6:図2A(2)のアンチセンス配列
配列番号7:図2A(3)のセンス配列
配列番号8:図2A(3)のアンチセンス配列
配列番号9:図2A(4)のセンス配列
配列番号10:図2A(4)のアンチセンス配列
配列番号11:図2A(5)のセンス配列
配列番号12:図2A(5)のアンチセンス配列
配列番号13:図6(16)のセンス配列
配列番号14:図6(16)のアンチセンス配列
配列番号15:図6(22)のセンス配列
配列番号16:図6(22)のアンチセンス配列
配列番号17:図6(23)のセンス配列
配列番号18:図6(23)のアンチセンス配列
配列番号19:図6(24)のセンス配列
配列番号20:図6(24)のアンチセンス配列
配列番号21:図7(17)のセンス配列
配列番号22:図7(17)のアンチセンス配列
配列番号23:図7(18)のセンス配列
配列番号24:図7(18)のアンチセンス配列
配列番号25:図7(23)-(1)のセンス配列
配列番号26:図7(23)-(1)のアンチセンス配列
配列番号27:図7(23)-(2)のセンス配列
配列番号28:図7(23)-(2)のアンチセンス配列
配列番号29:図7(23)-(3)のセンス配列
配列番号30:図7(23)-(3)のアンチセンス配列
配列番号31:図10(1)’のセンス配列
配列番号32:図10(1)’のアンチセンス配列
配列番号33:図10(6)’のセンス配列
配列番号34:図10(6)’のアンチセンス配列
配列番号35:図12(23)のセンス配列
配列番号36:図12(23)のアンチセンス配列
配列番号37:図19(41)のセンス配列
配列番号38:図19(41)のアンチセンス配列
配列番号39:図19(42)のセンス配列
配列番号40:図19(42)のアンチセンス配列
配列番号41:図19(43)のセンス配列
配列番号42:図19(43)のアンチセンス配列
配列番号43:図19(44)のセンス配列
配列番号44:図19(44)のアンチセンス配列
配列番号45:図19(45)のセンス配列
配列番号46:図19(45)のアンチセンス配列
配列番号47:図23(51)のセンス配列
配列番号48:図23(51)のアンチセンス配列
配列番号49:図23(52)のセンス配列
配列番号50:図23(52)のアンチセンス配列
配列番号51:図23(53)のセンス配列
配列番号52:図23(53)のアンチセンス配列
配列番号53:図23(54)のセンス配列
配列番号54:図23(54)のアンチセンス配列
配列番号55:図23(55)のセンス配列
配列番号56:図23(55)のアンチセンス配列
配列番号57:S-TuD NC2(図18、図22)のセンス配列
配列番号58:S-TuD NC2(図18、図22)のアンチセンス配列
配列番号59:図32(2)’のセンス配列
配列番号60:図32(2)’のアンチセンス配列
配列番号61:図32(7)’のセンス配列
配列番号62:図32(7)’のアンチセンス配列
配列番号63:図32(8)’のセンス配列
配列番号64:図32(8)’のアンチセンス配列
配列番号65:図34(1)”のセンス配列
配列番号66:図34(1)”のアンチセンス配列
配列番号67:図34(2)”のセンス配列
配列番号68:図34(2)”のアンチセンス配列
配列番号69:図34(3)”のセンス配列
配列番号70:図34(3)”のアンチセンス配列
配列番号71:図34(4)”のセンス配列
配列番号72:図34(4)”のアンチセンス配列
配列番号73:図34(5)”のセンス配列
配列番号74:図34(5)”のアンチセンス配列
配列番号75:図17のpsiCHECK2-T200c-3p-s(センス配列)
配列番号76:図17のpsiCHECK2-T200c-3p-a(アンチセンス配列)
配列番号77:図17のpsiCHECK2-T199a-3px3-s(センス配列)
配列番号78:図17のpsiCHECK2-T199a-3px3-a(アンチセンス配列)
配列番号79:図17のpsiCHECK2-T21-5p-s(センス配列)
配列番号80:図17のpsiCHECK2-T21-5p-a(アンチセンス配列)
Claims (27)
- RNAまたはその類縁体を含むmiRNA阻害複合体であって、該miRNA阻害複合体は、少なくとも1つの二本鎖構造およびmiRNA結合配列を含み、該miRNA結合配列の2つの鎖が、該二本鎖構造の少なくとも片端の2つの鎖に一本ずつ結合しており、該miRNA阻害複合体は少なくとも1つの架橋核酸(BNA)を含む、miRNA阻害複合体。
- 前記BNAは2’位側で酸素および炭素からなる群より選択される少なくとも1つの原子を介し、4’位側で炭素と炭素および窒素からなる群より選択される少なくとも1つ原子を介して架橋されたBNAを含む、請求項1に記載の複合体。
- 前記BNAは
(式中、R1、R1’、R2、R2’、およびR3は、それぞれ独立して、水素原子、置換または非置換のアルキル基、置換または非置換のアルケニル基、置換または非置換のシクロアルキル基、置換または非置換のアリール基、置換または非置換のアラルキル基、置換または非置換のアシル基、置換または非置換のスルホニル基、置換または非置換のシリル基、および機能性分子ユニット置換基からなる群より選択される基を示し、mは、0~2の整数であり、Baseは、アデニニル基、チミニル基、ウラシリル基、イノシニル基、シトシニル基、グアニニル基、およびメチルシトシニル基からなる群より選択される基を示し、nは、1~3の整数であり、qは0または1の整数である。)で示される2’,4’置換架橋核酸を含む、請求項1に記載の複合体。 - 前記BNAはBNANC(NMe)である、請求項1に記載の複合体。
- 前記BNAは、前記二本鎖構造部分の少なくとも一方の鎖および前記miRNA結合配列の相補鎖の少なくとも一つの鎖に含まれる、請求項1~6のいずれか一項に記載の複合体。
- 前記BNAは、前記二本鎖構造部分の少なくとも一方の鎖に含まれる、請求項1~6のいずれか一項に記載の複合体。
- 前記BNAは、前記二本鎖構造部分の両方の鎖に含まれる、請求項8に記載の複合体。
- 前記BNAは2つ以上含まれる、請求項1に記載の複合体。
- 前記BNAは4つ以上含まれる、請求項1に記載の複合体。
- 前記BNAは6つ以上含まれる、請求項1に記載の複合体。
- 前記複合体は、前記二本鎖構造を2つ以上含み、該二本鎖構造の第1の二本鎖構造の片端の2つの鎖にmiRNA結合配列を含む鎖がそれぞれ1本ずつ結合しており、該2つ以上の二本鎖構造に挟まれるように、該鎖のそれぞれの他端が、該2つ以上の二本鎖構造の第2の二本鎖構造の2つの鎖にそれぞれ結合している、請求項1~12のいずれか一項に記載の複合体。
- 前記miRNA結合配列を含む2つの鎖の末端が、リンカーを介して結合している、請求項1~13のいずれか一項に記載の複合体。
- 前記リンカーの長さは1~5塩基長である、請求項14に記載の複合体。
- 前記二本鎖の構造は、少なくとも6塩基長である、請求項1~15のいずれか一項に記載の複合体。
- 前記二本鎖の構造は、少なくとも8塩基長である、請求項1~16のいずれか一項に記載の複合体。
- 前記二本鎖の構造は、少なくとも10塩基長である、請求項1~17のいずれか一項に記載の複合体。
- 前記二本鎖の構造は、少なくとも15塩基長である、請求項1~18のいずれか一項に記載の複合体。
- 前記二本鎖の構造は、少なくとも18塩基長である、請求項1~19のいずれか一項に記載の複合体。
- 前記二本鎖の構造は、50塩基長以下である、請求項16~20のいずれか一項に記載の複合体。
- 2から5つのmiRNA結合配列を含む、請求項1~21のいずれか一項に記載の複合体。
- 2つのmiRNA結合配列を含む、請求項22に記載の複合体。
- 請求項1~24のいずれか一項に記載の複合体を構成するRNAまたはその類縁体。
- 請求項1~24のいずれか一項に記載の複合体または請求項25に記載のRNAまたはその類縁体を製造する方法であって、
A)化学合成により、リボ核酸およびBNAを用いて、目的とするRNAまたはその類縁体の一本鎖の保護体およびその相補体の保護体を合成する工程;
B)生成した該一本鎖の保護体およびその相補体をそれぞれ脱保護する工程;ならびに
必要に応じてC)脱保護した該一本鎖のそれぞれを二本鎖形成条件に配置して二本鎖を形成する工程
を包含する方法。 - 請求項1~24のいずれか一項に記載の複合体を含む医薬。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16845971.7A EP3351632A4 (en) | 2015-09-18 | 2016-09-16 | STRUCTURALLY ENHANCED MICRO-RNA INHIBITOR S-TUD |
JP2017540518A JP6882735B2 (ja) | 2015-09-18 | 2016-09-16 | 構造強化されたmiRNA阻害剤S−TuD |
US15/761,018 US10844376B2 (en) | 2015-09-18 | 2016-09-16 | Structurally-enhanced miRNA inhibitor S-TuD |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-185365 | 2015-09-18 | ||
JP2015185365 | 2015-09-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017047097A1 true WO2017047097A1 (ja) | 2017-03-23 |
Family
ID=58288564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/004252 WO2017047097A1 (ja) | 2015-09-18 | 2016-09-16 | 構造強化されたmiRNA阻害剤S-TuD |
Country Status (4)
Country | Link |
---|---|
US (1) | US10844376B2 (ja) |
EP (1) | EP3351632A4 (ja) |
JP (1) | JP6882735B2 (ja) |
WO (1) | WO2017047097A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018169063A1 (ja) * | 2017-03-17 | 2018-09-20 | 国立大学法人千葉大学 | 構造強化されたS-TuDを用いた新規がん治療法 |
WO2020203896A1 (ja) * | 2019-03-29 | 2020-10-08 | シスメックス株式会社 | 新規人工核酸、その製造方法及び用途 |
JP2021525762A (ja) * | 2018-05-31 | 2021-09-27 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーションKorea University Research And Business Foundation | マイクロrnaを抑制する変形核酸及びその用途 |
WO2022065413A1 (ja) * | 2020-09-25 | 2022-03-31 | 株式会社理研ジェネシス | 新規人工核酸、その製造方法及び用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021570A1 (ja) * | 2003-08-28 | 2005-03-10 | Gene Design, Inc. | N−0結合性架橋構造型新規人工核酸 |
WO2010047216A1 (ja) * | 2008-10-23 | 2010-04-29 | 国立大学法人 東京大学 | microRNAの機能阻害法 |
-
2016
- 2016-09-16 JP JP2017540518A patent/JP6882735B2/ja active Active
- 2016-09-16 US US15/761,018 patent/US10844376B2/en active Active
- 2016-09-16 EP EP16845971.7A patent/EP3351632A4/en active Pending
- 2016-09-16 WO PCT/JP2016/004252 patent/WO2017047097A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021570A1 (ja) * | 2003-08-28 | 2005-03-10 | Gene Design, Inc. | N−0結合性架橋構造型新規人工核酸 |
WO2010047216A1 (ja) * | 2008-10-23 | 2010-04-29 | 国立大学法人 東京大学 | microRNAの機能阻害法 |
Non-Patent Citations (4)
Title |
---|
ABDUR RAHMAN, S. M. ET AL.: "Design, synthesis, and properties of 2',4'-BNANC: a bridged nucleic acid analogue", J. AM. CHEM. SOC., vol. 130, 2008, pages 4886 - 4896, XP 055031784 * |
HARAGUCHI, TAKESHI ET AL.: "A potent 2'-O- methylated RNA-based microRNA inhibitor with unique secondary structures", NUCLEIC ACIDS RES., vol. 40, no. e58, 2012, pages 1 - 13, XP 055199021 * |
See also references of EP3351632A4 * |
TAKESHI HARAGUCHI ET AL.: "2'-OME RNA Oligo o Kiban to shita Dokutoku no Nijikozo o Motsu Shinki microRNA Sogaizai S-TuD", GENE & MEDICINE MOOK23 RINSHO.SOYAKU RIYO GA MIETEKITA MICRORNA, 2012, pages 169 - 175, XP009510058 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018169063A1 (ja) * | 2017-03-17 | 2018-09-20 | 国立大学法人千葉大学 | 構造強化されたS-TuDを用いた新規がん治療法 |
US11479769B2 (en) | 2017-03-17 | 2022-10-25 | National University Corporation Chiba University | Technique for treating cancer using structurally-reinforced S-TuD |
JP2021525762A (ja) * | 2018-05-31 | 2021-09-27 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーションKorea University Research And Business Foundation | マイクロrnaを抑制する変形核酸及びその用途 |
JP7162918B2 (ja) | 2018-05-31 | 2022-10-31 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | マイクロrnaを抑制する変形核酸及びその用途 |
WO2020203896A1 (ja) * | 2019-03-29 | 2020-10-08 | シスメックス株式会社 | 新規人工核酸、その製造方法及び用途 |
JP7413362B2 (ja) | 2019-03-29 | 2024-01-15 | シスメックス株式会社 | 新規人工核酸、その製造方法及び用途 |
WO2022065413A1 (ja) * | 2020-09-25 | 2022-03-31 | 株式会社理研ジェネシス | 新規人工核酸、その製造方法及び用途 |
Also Published As
Publication number | Publication date |
---|---|
EP3351632A1 (en) | 2018-07-25 |
US10844376B2 (en) | 2020-11-24 |
US20180223281A1 (en) | 2018-08-09 |
JPWO2017047097A1 (ja) | 2018-07-05 |
JP6882735B2 (ja) | 2021-06-02 |
EP3351632A4 (en) | 2019-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106795200B (zh) | Galnac亚磷酰胺、其核酸缀合物及其用途 | |
EP2961841B1 (en) | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent | |
JP5816556B2 (ja) | 治療剤のためのunaオリゴマー構造 | |
JP2019069971A (ja) | キラル制御 | |
CN111465694A (zh) | 用于抑制细胞中lpa的表达的核酸 | |
US10011833B2 (en) | Bridged bicyclic nucleosides | |
JP6882735B2 (ja) | 構造強化されたmiRNA阻害剤S−TuD | |
Meng et al. | Oligonucleotide analogues with cationic backbone linkages | |
CN115397436A (zh) | 用于抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
KR20160067901A (ko) | RNA 간섭에 사용하기 위한 RNAi 작용제를 위한 3'' 말단 캡 | |
JP2016130232A (ja) | オリゴヌクレオチド | |
Koch et al. | Locked nucleic acid | |
US20040171030A1 (en) | Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation | |
US20040146902A1 (en) | Structural motifs and oligomeric compounds and their use in gene modulation | |
JP6974872B2 (ja) | ヘテロ二本鎖型antimiR | |
JP2014050389A (ja) | マイクロ−rnaおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加 | |
JP7306653B2 (ja) | 構造強化されたS-TuDを用いた新規がん治療法 | |
US20040171029A1 (en) | 2'-Fluoro substituted oligomeric compounds and compositions for use in gene modulations | |
WO2023080225A1 (ja) | 脊髄小脳失調症治療用医薬組成物 | |
WO2020262555A1 (ja) | 核酸医薬副作用軽減剤、該核酸医薬副作用軽減剤を含む医薬組成物、並びに核酸医薬の副作用惹起性を軽減する方法 | |
WO2022256354A1 (en) | Short duplex dna as a novel gene silencing technology and use thereof | |
WO2024124216A1 (en) | Short duplex rna with interspersed deoxyribonucleotides as a gene silencing technology and use thereof | |
WO2024124213A1 (en) | Asymmetric short duplex rna with interspersed deoxyribonucleotides as a gene silencing technology and use thereof | |
WO2022256351A1 (en) | Asymmetric short duplex dna as a novel gene silencing technology and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16845971 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017540518 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15761018 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016845971 Country of ref document: EP |